Abstract
Ocular manifestations are relatively common among children with rheumatic diseases. Many of these disorders may lead to vision loss and life-long disability if not detected and treated early. The ocular complications of JIA are well known by both ophthalmologists and pediatric specialists, yet the treatment of the associated chronic uveitis remains a challenge. Among the other childhood rheumatic diseases, a variety of ocular manifestations can occur including conjunctivitis, scleritis, keratoconjunctivitis sicca keratitis, various forms of uveitis, retinal vasculitis, optic neuritis, and rarely orbital disease. A team-based approach to screening, treatment and monitoring is recommended for children with these diseases. Close collaboration between the ophthalmologist, pediatric rheumatologist as well as other specialists is essential to maintain optimal visual function for these children.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Fink CW. Proposal for the development of classification criteria for idiopathic arthritides of childhood. J Rheumatol. 1995;22(8):1566–9.
Prahalad S, Glass DN. A comprehensive review of the genetics of juvenile idiopathic arthritis. Pediatr Rheum Online J. 2008;6:11.
Prakken B, Albani S, Martini A. Juvenile idiopathic arthritis. Lancet. 2011;377(9783):2138–49.
Calabro JJ, Marchesano JM. Juvenile rheumatoid arthritis—current concepts. New Engl J Med. 1967;277(696–699):746–9.
Foster CS. Diagnosis and treatment of juvenile idiopathic arthritis-associated uveitis. Curr Opin Ophthalmol. 2003;14(6):395–8.
Brewer Jr EJ, Bass J, Baum J, Cassidy JT, Fink C, Jacobs J, et al. Current proposed revision of JRA Criteria. JRA Criteria Subcommittee of the Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Section of The Arthritis Foundation. Arthritis Rheum. 1977;20(2 Suppl):195–9.
Hofer M, Southwood TR. Classification of childhood arthritis. Best Pract Res Clin Rheumatol. 2002;16(3):379–96.
Petty RE. Classification of childhood arthritis: a work in progress. Baillieres Clin Rheumatol. 1998;12(2):181–90.
Duffy CM, Colbert RA, Laxer RM, Schanberg LE, Bowyer SL. Nomenclature and classification in chronic childhood arthritis: time for a change? Arthritis Rheum. 2005;52(2):382–5.
Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31(2):390–2.
Rauz S, Murray PI, Southwood TR. Juvenile idiopathic arthritis and uveitis: the classification conundrum. Eye (Lond). 2000;14(Pt 6):817–20.
Still GF. On a form of chronic joint disease in children. Med Chir Trans. 1897;80:47–60.9.
Ohm J. Bandförmige Hornhauttrübung bei einem neunjährigen Mädchen. Klin Monatsbl f Augenh. 1910;48:243–6.
Rosenberg AM. Uveitis associated with juvenile rheumatoid arthritis. Semin Arthritis Rheum. 1987;16(3):158–73.
Manners PJ, Bower C. Worldwide prevalence of juvenile arthritis why does it vary so much? J Rheumatol. 2002;29(7):1520–30.
Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh CK, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum. 2008;58(1):15–25.
Saurenmann RK, Levin AV, Feldman BM, Rose JB, Laxer RM, Schneider R, et al. Prevalence, risk factors, and outcome of uveitis in juvenile idiopathic arthritis: a long-term followup study. Arthritis Rheum. 2007;56(2):647–57.
Andersson Gare B, Fasth A, Andersson J, Berglund G, Ekstrom H, Eriksson M, et al. Incidence and prevalence of juvenile chronic arthritis: a population survey. Ann Rheum Dis. 1987;46(4):277–81.
Peterson LS, Mason T, Nelson AM, O’Fallon WM, Gabriel SE. Juvenile rheumatoid arthritis in Rochester, Minnesota 1960–1993. Is the epidemiology changing? Arthritis Rheum. 1996;39(8):1385–90.
Gare BA, Fasth A. Epidemiology of juvenile chronic arthritis in southwestern Sweden: a 5-year prospective population study. Pediatrics. 1992;90(6):950–8.
Berntson L, Andersson Gare B, Fasth A, Herlin T, Kristinsson J, Lahdenne P, et al. Incidence of juvenile idiopathic arthritis in the Nordic countries. A population based study with special reference to the validity of the ILAR and EULAR criteria. J Rheumatol. 2003;30(10):2275–82.
Borchers AT, Selmi C, Cheema G, Keen CL, Shoenfeld Y, Gershwin ME. Juvenile idiopathic arthritis. Autoimmun Rev. 2006;5(4):279–98.
Weiss JE, Ilowite NT. Juvenile Idiopathic Arthritis. Rheum Dis Clin North Am. 2007;33(3):441–70.
Schaller JG. Juvenile rheumatoid arthritis. Pediatr Rev. 1997;18(10):337–49.
Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet. 2007;369(9563):767–78.
Svantesson H, Akesson A, Eberhardt K, Elborgh R. Prognosis in juvenile rheumatoid arthritis with systemic onset. A follow-up study. Scand J Rheumatol. 1983;12(2):139–44.
Petty RE, Smith JR, Rosenbaum JT. Arthritis and uveitis in children. A pediatric rheumatology perspective. Am J Ophthalmol. 2003;135(6):879–84.
Al-Matar MJ, Petty RE, Tucker LB, Malleson PN, Schroeder ML, Cabral DA. The early pattern of joint involvement predicts disease progression in children with oligoarticular (pauciarticular) juvenile rheumatoid arthritis. Arthritis Rheum. 2002;46(10):2708–15.
Guillaume S, Prieur AM, Coste J, Job-Deslandre C. Long-term outcome and prognosis in oligoarticular-onset juvenile idiopathic arthritis. Arthritis Rheum. 2000;43(8):1858–65.
Felici E, Novarini C, Magni-Manzoni S, Pistorio A, Magnani A, Bozzola E, et al. Course of joint disease in patients with antinuclear antibody-positive juvenile idiopathic arthritis. J Rheumatol. 2005;32(9):1805–10.
Petty RE. Current knowledge of the etiology and pathogenesis of chronic uveitis accompanying juvenile rheumatoid arthritis. Rheum Dis Clin North Am. 1987;13(1):19–36.
Martini A. Are the number of joints involved or the presence of psoriasis still useful tools to identify homogeneous disease entities in juvenile idiopathic arthritis? J Rheumatol. 2003;30(9):1900–3.
Ravelli A, Felici E, Magni-Manzoni S, Pistorio A, Novarini C, Bozzola E, et al. Patients with antinuclear antibody-positive juvenile idiopathic arthritis constitute a homogeneous subgroup irrespective of the course of joint disease. Arthritis Rheum. 2005;52(3):826–32.
Wallace CA, Huang B, Bandeira M, Ravelli A, Giannini EH. Patterns of clinical remission in select categories of juvenile idiopathic arthritis. Arthritis Rheum. 2005;52(11):3554–62.
Foster HE, Marshall N, Myers A, Dunkley P, Griffiths ID. Outcome in adults with juvenile idiopathic arthritis: a quality of life study. Arthritis Rheum. 2003;48(3):767–75.
Oen K, Malleson PN, Cabral DA, Rosenberg AM, Petty RE, Cheang M. Disease course and outcome of juvenile rheumatoid arthritis in a multicenter cohort. J Rheumatol. 2002;29(9):1989–99.
Zak M, Pedersen FK. Juvenile chronic arthritis into adulthood: a long-term follow-up study. Rheumatology (Oxford). 2000;39(2):198–204.
Malleson PN, Fung MY, Rosenberg AM. The incidence of pediatric rheumatic diseases: results from the Canadian Pediatric Rheumatology Association Disease Registry. J Rheumatol. 1996;23(11):1981–7.
Shore A, Ansell BM. Juvenile psoriatic arthritis—an analysis of 60 cases. J Pediatr. 1982;100(4):529–35.
Southwood TR, Petty RE, Malleson PN, Delgado EA, Hunt DW, Wood B, et al. Psoriatic arthritis in children. Arthritis Rheum. 1989;32(8):1007–13.
Cabral DA, Petty RE, Malleson PN, Ensworth S, McCormick AQ, Shroeder ML. Visual prognosis in children with chronic anterior uveitis and arthritis. J Rheumatol. 1994;21(12):2370–5.
Zierhut M, Michels H, Stubiger N, Besch D, Deuter C, Heiligenhaus A. Uveitis in children. Int Ophthalmol Clin. 2005;45(2):135–56.
Stoll ML, Zurakowski D, Nigrovic LE, Nichols DP, Sundel RP, Nigrovic PA. Patients with juvenile psoriatic arthritis comprise two distinct populations. Arthritis Rheum. 2006;54(11):3564–72.
Roberton DM, Cabral DA, Malleson PN, Petty RE. Juvenile psoriatic arthritis: followup and evaluation of diagnostic criteria. J Rheumatol. 1996;23(1):166–70.
Lang BA, Shore A. A review of current concepts on the pathogenesis of juvenile rheumatoid arthritis. J Rheumatol Suppl. 1990;21:1–15.
Cabral DA, Oen KG, Petty RE. SEA syndrome revisited: a longterm followup of children with a syndrome of seronegative enthesopathy and arthropathy. J Rheumatol. 1992;19(8):1282–5.
Flato B, Hoffmann-Vold AM, Reiff A, Forre O, Lien G, Vinje O. Long-term outcome and prognostic factors in enthesitis-related arthritis: a case-control study. Arthritis Rheum. 2006;54(11):3573–82.
Chylack Jr LT. The ocular manifestations of juvenile rheumatoid arthritis. Arthritis Rheum. 1977;20(2 Suppl):217–23.
Chalom EC, Goldsmith DP, Koehler MA, Bittar B, Rose CD, Ostrov BE, et al. Prevalence and outcome of uveitis in a regional cohort of patients with juvenile rheumatoid arthritis. J Rheumatol. 1997;24(10):2031–4.
Rosenbaum JT. Iridocyclitis is not characteristic of Still’s disease. West J Med. 1985;143(2):252.
Rosenberg AMBM, Fong KC. The relationship between uveitis and antinuclear antidobies (ANA) in subjects with and without juvenile rheumatoid arthritis (JRA). Arthritis Rheum. 1986;29:S67.
Sherry DD, Mellins ED, Wedgwood RJ. Decreasing severity of chronic uveitis in children with pauciarticular arthritis. Am J Dis Child. 1991;145(9):1026–8.
Cimaz RG, Fink CW. The articular prognosis of pauciarticular onset juvenile arthritis is not influenced by the presence of uveitis. J Rheumatol. 1996;23(2):357–9.
Kotaniemi K, Kautiainen H, Karma A, Aho K. Occurrence of uveitis in recently diagnosed juvenile chronic arthritis: a prospective study. Ophthalmology. 2001;108(11):2071–5.
Kesen MR, Setlur V, Goldstein DA. Juvenile idiopathic arthritis-related uveitis. Int Ophthalmol Clin. 2008;48(3):21–38.
Keenan JD, Tessler HH, Goldstein DA. Granulomatous inflammation in juvenile idiopathic arthritis-associated uveitis. J AAPOS. 2008;12(6):546–50.
Sabri K, Saurenmann RK, Silverman ED, Levin AV. Course, complications, and outcome of juvenile arthritis-related uveitis. J AAPOS. 2008;12(6):539–45.
Kanski JJ. Anterior uveitis in juvenile rheumatoid arthritis. Arch Ophthalmol. 1977;95(10):1794–7.
Key 3rd SN, Kimura SJ. Iridocyclitis associated with juvenile rheumatoid arthritis. Am J Ophthalmol. 1975;80(3 Pt 1):425–9.
Hoeve M, Kalinina Ayuso V, Schalij-Delfos NE, Los LI, Rothova A, de Boer JH. The clinical course of juvenile idiopathic arthritis-associated uveitis in childhood and puberty. Br J Ophthalmol. 2012;96(6):852–6.
Saurenmann RK, Levin AV, Feldman BM, Laxer RM, Schneider R, Silverman ED. Risk factors for development of uveitis differ between girls and boys with juvenile idiopathic arthritis. Arthritis Rheum. 2010;62(6):1824–8.
Chia A, Lee V, Graham EM, Edelsten C. Factors related to severe uveitis at diagnosis in children with juvenile idiopathic arthritis in a screening program. Am J Ophthalmol. 2003;135(6):757–62.
Dana MR, Merayo-Lloves J, Schaumberg DA, Foster CS. Visual outcomes prognosticators in juvenile rheumatoid arthritis-associated uveitis. Ophthalmology. 1997;104(2):236–44.
Woreta F, Thorne JE, Jabs DA, Kedhar SR, Dunn JP. Risk factors for ocular complications and poor visual acuity at presentation among patients with uveitis associated with juvenile idiopathic arthritis. Am J Ophthalmol. 2007;143(4):647–55.
Zak M, Fledelius H, Pedersen FK. Ocular complications and visual outcome in juvenile chronic arthritis: a 25-year follow-up study. Acta Ophthalmol Scand. 2003;81(3):211–5.
Thorne JE, Woreta F, Kedhar SR, Dunn JP, Jabs DA. Juvenile idiopathic arthritis-associated uveitis: incidence of ocular complications and visual acuity loss. Am J Ophthalmol. 2007;143(5):840–6.
Smiley WK. Iridocyclitis in Still’s disease. Prognosis and steroid treatment. Trans Ophthalmol Soc U K. 1965;85:351–6.
Cassidy JT, Sullivan DB, Petty RE. Clinical patterns of chronic iridocyclitis in children with juvenile rheumatoid arthritis. Arthritis Rheum. 1977;20(2 Suppl):224–7.
Wolf MD, Lichter PR, Ragsdale CG. Prognostic factors in the uveitis of juvenile rheumatoid arthritis. Ophthalmology. 1987;94(10):1242–8.
Kanski JJ. Uveitis in juvenile chronic arthritis. Clin Exp Rheumatol. 1990;8(5):499–503.
Kump LI, Castaneda RA, Androudi SN, Reed GF, Foster CS. Visual outcomes in children with juvenile idiopathic arthritis-associated uveitis. Ophthalmology. 2006;113(10):1874–7.
Kalinina Ayuso V, Ten Cate HA, van der Does P, Rothova A, de Boer JH. Male gender as a risk factor for complications in uveitis associated with juvenile idiopathic arthritis. Am J Ophthalmol. 2010;149(6):994–9.e5.
Thorne JE, Woreta FA, Dunn JP, Jabs DA. Risk of cataract development among children with juvenile idiopathic arthritis-related uveitis treated with topical corticosteroids. Ophthalmology. 2010;117(7):1436–41.
Sijssens KM, Rothova A, Van De Vijver DA, Stilma JS, De Boer JH. Risk factors for the development of cataract requiring surgery in uveitis associated with juvenile idiopathic arthritis. Am J Ophthalmol. 2007;144(4):574–9.
Akinci A, Cakar N, Uncu N, Kara N, Acaroglu G. Keratoconjunctivitis sicca in juvenile rheumatoid arthritis. Cornea. 2007;26(8):941–4.
Jain V, Singh S, Sharma A. Keratonconjunctivitis sicca is not uncommon in children with juvenile rheumatoid arthritis. Rheumatol Int. 2001;20(4):159–62.
Kotaniemi KM, Salomaa PM, Sihto-Kauppi K, Saila HM, Kauppi MJ. An evaluation of dry eye symptoms and signs in a cohort of children with juvenile idiopathic arthritis. Clin Ophthalmol. 2009;3:271–5.
El-Shazly AA, Mohamed AA. Relation of dry eye to disease activity in juvenile rheumatoid arthritis. Eur J Ophthalmol. 2012;22(3):330–4.
Alves M, Dias AC, Rocha EM. Dry eye in childhood: epidemiological and clinical aspects. Ocul Surf. 2008;6(1):44–51.
Wang FM, Wertenbaker C, Behrens MM, Jacobs JC. Acquired Brown’s syndrome in children with juvenile rheumatoid arthritis. Ophthalmology. 1984;91(1):23–6.
Kemp AS, Searle C, Horne S. Transient Brown’s syndrome in juvenile chronic arthritis. Ann Rheum Dis. 1984;43(5):764–5.
Moore AT, Morin JD. Bilateral acquired inflammatory Brown’s syndrome. J Pediatr Ophthalmol Strabismus. 1985;22(1):26–30.
Killian PJ, McClain B, Lawless OJ. Brown’s syndrome. An unusual manifestation of rheumatoid arthritis. Arthritis Rheum. 1977;20(5):1080–4.
van Rossum M, van Soesbergen R, de Kort S, ten Cate R, Zwinderman AH, de Jong B, et al. Anti-cyclic citrullinated peptide (anti-CCP) antibodies in children with juvenile idiopathic arthritis. J Rheumatol. 2003;30(4):825–8.
Omar A, Abo-Elyoun I, Hussein H, Nabih M, Atwa H, Gad S, et al. Anti-cyclic citrullinated peptide (anti-CCP) antibody in juvenile idiopathic arthritis (JIA): correlations with disease activity and severity of joint damage (a multicenter trial). Joint Bone Spine. 2013;80(1):38–43.
Habib HM, Mosaad YM, Youssef HM. Anti-cyclic citrullinated peptide antibodies in patients with juvenile idiopathic arthritis. Immunol Invest. 2008;37(8):849–57.
Kwok JS, Hui KH, Lee TL, Wong W, Lau YL, Wong RW, et al. Anti-cyclic citrullinated peptide: diagnostic and prognostic values in juvenile idiopathic arthritis and rheumatoid arthritis in a Chinese population. Scand J Rheumatol. 2005;34(5):359–66.
Brunner J, Sitzmann FC. The diagnostic value of anti-cyclic citrullinated peptide (CCP) antibodies in children with Juvenile Idiopathic Arthritis. Clin Exp Rheumatol. 2006;24(4):449–51.
McCann LJ, Wedderburn LR, Hasson N. Juvenile idiopathic arthritis. Arch Dis Child Edu Pract Ed. 2006;91(2):ep29–36.
Poznanski AK. Radiological approaches to pediatric joint disease. J Rheumatol Suppl. 1992;33:78–93.
Reed MH, Wilmot DM. The radiology of juvenile rheumatoid arthritis. A review of the English language literature. J Rheumatol Suppl. 1991;31:2–22.
Magni-Manzoni S, Malattia C, Lanni S, Ravelli A. Advances and challenges in imaging in juvenile idiopathic arthritis. Nat Rev Rheumatol. 2012;8(6):329–36.
Kahn P. Juvenile idiopathic arthritis—an update on pharmacotherapy. Bull NYU Hosp Jt Dis. 2011;69(3):264–76.
Schaller JG. Therapy for childhood rheumatic diseases. Have we been doing enough? Arthritis Rheum. 1993;36(1):65–70.
Malleson PN. Management of childhood arthritis. Part 2: chronic arthritis. Arch Dis Child. 1997;76(6):541–4.
Prince FH, Otten MH, van Suijlekom-Smit LW. Diagnosis and management of juvenile idiopathic arthritis. BMJ. 2010;341:c6434.
Davies K, Cleary G, Foster H, Hutchinson E, Baildam E, British Society of Paediatric and Adolescent Rheumatology. BSPAR Standards of Care for children and young people with juvenile idiopathic arthritis. Rheumatology. 2010;49(7):1406–8.
Albers HM, Wessels JA, van der Straaten RJ, Brinkman DM, Suijlekom-Smit LW, Kamphuis SS, et al. Time to treatment as an important factor for the response to methotrexate in juvenile idiopathic arthritis. Arthritis Rheum. 2009;61(1):46–51.
van Rossum MA, van Soesbergen RM, Boers M, Zwinderman AH, Fiselier TJ, Franssen MJ, et al. Long-term outcome of juvenile idiopathic arthritis following a placebo-controlled trial: sustained benefits of early sulfasalazine treatment. Ann Rheum Dis. 2007;66(11):1518–24.
Minden K. Adult outcomes of patients with juvenile idiopathic arthritis. Horm Res. 2009;72 Suppl 1:20–5.
Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med. 2000;342(11):763–9.
Lovell DJ, Reiff A, Ilowite NT, Wallace CA, Chon Y, Lin SL, et al. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum. 2008;58(5):1496–504.
Lovell DJ, Ruperto N, Goodman S, Reiff A, Jung L, Jarosova K, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med. 2008;359(8):810–20.
Henrickson M, Reiff A. Prolonged efficacy of etanercept in refractory enthesitis-related arthritis. J Rheumatol. 2004;31(10):2055–61.
Horneff G, Schmeling H, Biedermann T, Foeldvari I, Ganser G, Girschick HJ, et al. The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis. 2004;63(12):1638–44.
Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med. 2005;201(9):1479–86.
Ruperto N, Lovell DJ, Quartier P, Paz E, Rubio-Perez N, Silva CA, et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet. 2008;372(9636):383–91.
Beukelman T, Patkar NM, Saag KG, Tolleson-Rinehart S, Cron RQ, DeWitt EM, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res. 2011;63(4):465–82.
Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 1998;41(9):1552–63.
Horneff G, De Bock F, Foeldvari I, Girschick HJ, Michels H, Moebius D, et al. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry. Ann Rheum Dis. 2009;68(4):519–25.
Cassidy J, Kivlin J, Lindsley C, Nocton J. Ophthalmologic examinations in children with juvenile rheumatoid arthritis. Pediatrics. 2006;117(5):1843–5.
Heiligenhaus A, Niewerth M, Ganser G, Heinz C, Minden K. Prevalence and complications of uveitis in juvenile idiopathic arthritis in a population-based nation-wide study in Germany: suggested modification of the current screening guidelines. Rheumatology (Oxford). 2007;46(6):1015–9.
Anesi SD, Foster CS. Importance of recognizing and preventing blindness from juvenile idiopathic arthritis-associated uveitis. Arthritis Care Res. 2012;64(5):653–7.
Heiligenhaus A, Michels H, Schumacher C, Kopp I, Neudorf U, Niehues T, et al. Evidence-based, interdisciplinary guidelines for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis. Rheumatol Int. 2012;32(5):1121–33.
Giannini EH, Brewer EJ, Kuzmina N, Shaikov A, Maximov A, Vorontsov I, et al. Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children’s Study Group. N Engl J Med. 1992;326(16):1043–9.
Goebel JC, Roesel M, Heinz C, Michels H, Ganser G, Heiligenhaus A. Azathioprine as a treatment option for uveitis in patients with juvenile idiopathic arthritis. Br J Ophthalmol. 2011;95(2):209–13.
Saurenmann RK, Levin AV, Rose JB, Parker S, Rabinovitch T, Tyrrell PN, et al. Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis. Rheumatology (Oxford). 2006;45(8):982–9.
Saurenmann RK, Levin AV, Feldman BM, Laxer RM, Schneider R, Silverman ED. Risk of new-onset uveitis in patients with juvenile idiopathic arthritis treated with anti-TNFalpha agents. J Pediatr. 2006;149(6):833–6.
Hooper PL, Rao NA, Smith RE. Cataract extraction in uveitis patients. Surv Ophthalmol. 1990;35(2):120–44.
Foster CS, Fong LP, Singh G. Cataract surgery and intraocular lens implantation in patients with uveitis. Ophthalmology. 1989;96(3):281–8.
Foster CS, Barrett F. Cataract development and cataract surgery in patients with juvenile rheumatoid arthritis-associated iridocyclitis. Ophthalmology. 1993;100(6):809–17.
Paikos P, Fotopoulou M, Papathanassiou M, Choreftaki P, Spyropoulos G. Cataract surgery in children with uveitis. J Pediat Ophth Strab. 2001;38(1):16–20.
Van Gelder RN, Leveque TK. Cataract surgery in the setting of uveitis. Curr Opin Ophthalmol. 2009;20(1):42–5.
Okhravi N, Morris A, Kok HS, Menezo V, Dowler JG, Hykin PG, et al. Intraoperative use of intravitreal triamcinolone in uveitic eyes having cataract surgery: pilot study. J Cataract Refract Surg. 2007;33(7):1278–83.
Dada T, Dhawan M, Garg S, Nair S, Mandal S. Safety and efficacy of intraoperative intravitreal injection of triamcinolone acetonide injection after phacoemulsification in cases of uveitic cataract. J Cataract Refract Surg. 2007;33(9):1613–8.
Holland GN. Intraocular lens implantation in patients with juvenile rheumatoid arthritis-associated uveitis: an unresolved management issue. Am J Ophthalmol. 1996;122(2):255–7.
Angeles-Han S, Yeh S. Prevention and management of cataracts in children with juvenile idiopathic arthritis-associated uveitis. Curr Rheumatol Rep. 2012;14(2):142–9.
Adan A, Gris O, Pelegrin L, Torras J, Corretger X. Explantation of intraocular lenses in children with juvenile idiopathic arthritis-associated uveitis. J Cataract Refract Surg. 2009;35(3):603–5.
Nemet AY, Raz J, Sachs D, Friling R, Neuman R, Kramer M, et al. Primary intraocular lens implantation in pediatric uveitis: a comparison of 2 populations. Arch Ophthalmol. 2007;125(3):354–60.
Terrada C, Julian K, Cassoux N, Prieur AM, Debre M, Quartier P, et al. Cataract surgery with primary intraocular lens implantation in children with uveitis: long-term outcomes. J Cataract Refract Surg. 2011;37(11):1977–83.
Sijssens KM, Los LI, Rothova A, Schellekens PA, van de Does P, Stilma JS, et al. Long-term ocular complications in aphakic versus pseudophakic eyes of children with juvenile idiopathic arthritis-associated uveitis. Br J Ophthalmol. 2010;94(9):1145–9.
Grajewski RS, Zurek-Imhoff B, Roesel M, Heinz C, Heiligenhaus A. Favourable outcome after cataract surgery with IOL implantation in uveitis associated with juvenile idiopathic arthritis. Acta Ophthalmol. 2011;90(7):657–62.
Kotaniemi K, Penttila H. Intraocular lens implantation in patients with juvenile idiopathic arthritis-associated uveitis. Ophthalmic Res. 2006;38(6):318–23.
Lam LA, Lowder CY, Baerveldt G, Smith SD, Traboulsi EI. Surgical management of cataracts in children with juvenile rheumatoid arthritis-associated uveitis. Am J Ophthalmol. 2003;135(6):772–8.
Zaborowski AG, Quinn AG, Gibbon CE, Banerjee S, Dick AD. Cataract surgery with primary intraocular lens implantation in children with chronic uveitis. Arch Ophthalmol. 2008;126(4):583–4.
Perry HD, Solomon R, Donnenfeld ED, Perry AR, Wittpenn JR, Greenman HE, et al. Evaluation of topical cyclosporine for the treatment of dry eye disease. Arch Ophthalmol. 2008;126(8):1046–50.
Pucci N, Novembre E, Cianferoni A, Lombardi E, Bernardini R, Caputo R, et al. Efficacy and safety of cyclosporine eyedrops in vernal keratoconjunctivitis. Ann Allergy Asthma Immunol. 2002;89(3):298–303.
Keklikci U, Soker SI, Sakalar YB, Unlu K, Ozekinci S, Tunik S. Efficacy of topical cyclosporin A 0.05% in conjunctival impression cytology specimens and clinical findings of severe vernal keratoconjunctivitis in children. Jpn J Ophthalmol. 2008;52(5):357–62.
Pucci N, Caputo R, Mori F, De Libero C, Di Grande L, Massai C, et al. Long-term safety and efficacy of topical cyclosporine in 156 children with vernal keratoconjunctivitis. Int J Immunopathol Pharmacol. 2010;23(3):865–71.
Mataftsi A, Subbu RG, Jones S, Nischal KK. The use of punctal plugs in children. Br J Ophthalmol. 2012;96(1):90–2.
Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25(11):1271–7.
Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725.
Petri M, Orbai AM, Alarcon GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677–86.
King KK, Kornreich HK, Bernstein BH, Singsen BH, Hanson V. The clinical spectrum of systemic lupus erythematosus in childhood. Arthritis Rheum. 1977;20(2 Suppl):287–94.
Tucker LB, Uribe AG, Fernandez M, Vila LM, McGwin G, Apte M, et al. Adolescent onset of lupus results in more aggressive disease and worse outcomes: results of a nested matched case-control study within LUMINA, a multiethnic US cohort (LUMINA LVII). Lupus. 2008;17(4):314–22.
Font J, Cervera R, Espinosa G, Pallares L, Ramos-Casals M, Jimenez S, et al. Systemic lupus erythematosus (SLE) in childhood: analysis of clinical and immunological findings in 34 patients and comparison with SLE characteristics in adults. Ann Rheum Dis. 1998;57(8):456–9.
Costallat LT, Coimbra AM. Systemic lupus erythematosus: clinical and laboratory aspects related to age at disease onset. Clin Exp Rheumatol. 1994;12(6):603–7.
Tucker LB. Making the diagnosis of systemic lupus erythematosus in children and adolescents. Lupus. 2007;16(8):546–9.
Rood MJ, ten Cate R, van Suijlekom-Smit LW, den Ouden EJ, Ouwerkerk FE, Breedveld FC, et al. Childhood-onset Systemic Lupus Erythematosus: clinical presentation and prognosis in 31 patients. Scand J Rheumatol. 1999;28(4):222–6.
Ginzler EM, Diamond HS, Weiner M, Schlesinger M, Fries JF, Wasner C, et al. A multicenter study of outcome in systemic lupus erythematosus. I. Entry variables as predictors of prognosis. Arthritis Rheum. 1982;25(6):601–11.
Klein-Gitelman M, Reiff A, Silverman ED. Systemic lupus erythematosus in childhood. Rheum Dis Clin North Am. 2002;28(3):561–77, vi–vii.
Hargraves MM, Richmond H, Morton R. Presentation of two bone marrow elements; the tart cell and the L.E. cell. Proc Staff Meet Mayo Clin. 1948;23(2):25–8.
Bergmeister R. Uber primare and Miliare Tuberkulose der Retina. Wien Med Schnschr. 1929;79:1116.
Baehr G, Klemperer P, Schifrin A. A diffuse disease of the peripheral circulation (usually associated with lupus erythematosus and endocarditis). Am J Med. 1952;13(5):591–6.
Lee BW, Yap HK, Yip WC, Low PS, Saw AH, Tay JS, et al. A 10 year review of systemic lupus erythematosus in Singapore children. Aust Paediatr J. 1987;23(3):163–5.
Ramirez Gomez LA, Uribe Uribe O, Osio Uribe O, Grisales Romero H, Cardiel MH, Wojdyla D, et al. Childhood systemic lupus erythematosus in Latin America. The GLADEL experience in 230 children. Lupus. 2008;17(6):596–604.
Carreno L, Lopez-Longo FJ, Monteagudo I, Rodriguez-Mahou M, Bascones M, Gonzalez CM, et al. Immunological and clinical differences between juvenile and adult onset of systemic lupus erythematosus. Lupus. 1999;8(4):287–92.
Mok CC, Mak A, Chu WP, To CH, Wong SN. Long-term survival of southern Chinese patients with systemic lupus erythematosus: a prospective study of all age-groups. Medicine. 2005;84(4):218–24.
Kamphuis S, Silverman ED. Prevalence and burden of pediatric-onset systemic lupus erythematosus. Nat Rev Rheumatol. 2010;6(9):538–46.
Hiraki LT, Benseler SM, Tyrrell PN, Hebert D, Harvey E, Silverman ED. Clinical and laboratory characteristics and long-term outcome of pediatric systemic lupus erythematosus: a longitudinal study. J Pediatr. 2008;152(4):550–6.
Pluchinotta FR, Schiavo B, Vittadello F, Martini G, Perilongo G, Zulian F. Distinctive clinical features of pediatric systemic lupus erythematosus in three different age classes. Lupus. 2007;16(8):550–5.
Cooper GS, Parks CG, Treadwell EL, St Clair EW, Gilkeson GS, Cohen PL, et al. Differences by race, sex and age in the clinical and immunologic features of recently diagnosed systemic lupus erythematosus patients in the southeastern United States. Lupus. 2002;11(3):161–7.
Peschken CA, Katz SJ, Silverman E, Pope JE, Fortin PR, Pineau C, et al. The 1000 Canadian faces of lupus: determinants of disease outcome in a large multiethnic cohort. J Rheumatol. 2009;36(6):1200–8.
McCarty DJ, Manzi S, Medsger Jr TA, Ramsey-Goldman R, LaPorte RE, Kwoh CK. Incidence of systemic lupus erythematosus. Race and gender differences. Arthritis Rheum. 1995;38(9):1260–70.
Hiraki LT, Benseler SM, Tyrrell PN, Harvey E, Hebert D, Silverman ED. Ethnic differences in pediatric systemic lupus erythematosus. J Rheumatol. 2009;36(11):2539–46.
Pons-Estel GJ, Alarcon GS, Scofield L, Reinlib L, Cooper GS. Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthritis Rheum. 2010;39(4):257–68.
Gottlieb BS, Ilowite NT. Systemic lupus erythematosus in children and adolescents. Pediatr Rev. 2006;27(9):323–30.
Levy DM, Kamphuis S. Systemic lupus erythematosus in children and adolescents. Pediatr Clin North Am. 2012;59(2):345–64.
Fiehn C, Hajjar Y, Mueller K, Waldherr R, Ho AD, Andrassy K. Improved clinical outcome of lupus nephritis during the past decade: importance of early diagnosis and treatment. Ann Rheum Dis. 2003;62(5):435–9.
Costenbader KH, Desai A, Alarcon GS, Hiraki LT, Shaykevich T, Brookhart MA, et al. Trends in the incidence, demographics, and outcomes of end-stage renal disease due to lupus nephritis in the US from 1995 to 2006. Arthritis Rheum. 2011;63(6):1681–8.
Benseler SM, Silverman ED. Systemic lupus erythematosus. Pediatr Clin North Am. 2005;52(2):443–67, vi.
Brunner HI, Jones OY, Lovell DJ, Johnson AM, Alexander P, Klein-Gitelman MS. Lupus headaches in childhood-onset systemic lupus erythematosus: relationship to disease activity as measured by the systemic lupus erythematosus disease activity index (SLEDAI) and disease damage. Lupus. 2003;12(8):600–6.
Pego-Reigosa JM, Isenberg DA. Psychosis due to systemic lupus erythematosus: characteristics and long-term outcome of this rare manifestation of the disease. Rheumatology (Oxford). 2008;47(10):1498–502.
Sibbitt Jr WL, Brandt JR, Johnson CR, Maldonado ME, Patel SR, Ford CC, et al. The incidence and prevalence of neuropsychiatric syndromes in pediatric onset systemic lupus erythematosus. J Rheumatol. 2002;29(7):1536–42.
Nguyen QD, Foster CS. Systemic lupus erythematosus and the eye. Int Ophthalmol Clin. 1998;38(1):33–60.
Davies JB, Rao PK. Ocular manifestations of systemic lupus erythematosus. Curr Opin Ophthalmol. 2008;19(6):512–8.
Peponis V, Kyttaris VC, Tyradellis C, Vergados I, Sitaras NM. Ocular manifestations of systemic lupus erythematosus: a clinical review. Lupus. 2006;15(1):3–12.
Palejwala NV, Walia HS, Yeh S. Ocular manifestations of systemic lupus erythematosus: a review of the literature. Autoimmun Dis. 2012;2012:290898.
Read RW. Clinical mini-review: systemic lupus erythematosus and the eye. Ocul Immunol Inflamm. 2004;12(2):87–99.
Gold DH, Morris DA, Henkind P. Ocular findings in systemic lupus erythematosus. Br J Ophthalmol. 1972;56(11):800–4.
Klinkhoff AV, Beattie CW, Chalmers A. Retinopathy in systemic lupus erythematosus: relationship to disease activity. Arthritis Rheum. 1986;29(9):1152–6.
Stafford-Brady FJ, Urowitz MB, Gladman DD, Easterbrook M. Lupus retinopathy. Patterns, associations, and prognosis. Arthritis Rheum. 1988;31(9):1105–10.
Al-Mayouf SM, Al-Hemidan AI. Ocular manifestations of systemic lupus erythematosus in children. Saudi Med J. 2003;24(9):964–6.
Hoffman IE, Lauwerys BR, De Keyser F, Huizinga TW, Isenberg D, Cebecauer L, et al. Juvenile-onset systemic lupus erythematosus: different clinical and serological pattern than adult-onset systemic lupus erythematosus. Ann Rheum Dis. 2009;68(3):412–5.
Read RW, Weiss AH, Sherry DD. Episcleritis in childhood. Ophthalmology. 1999;106(12):2377–9.
Harel L, Sandborg C, Lee T, von Scheven E. Neuropsychiatric manifestations in pediatric systemic lupus erythematosus and association with antiphospholipid antibodies. J Rheumatol. 2006;33(9):1873–7.
Almeida RT, Aikawa NE, Sallum AM, Jesus AA, Sa LC, Silva CA. Irreversible blindness in juvenile systemic lupus erythematosus. Lupus. 2011;20(1):95–7.
Amirlak I, Narchi H. Isolated orbital pseudotumor as the presenting sign of systemic lupus erythematosus. J Pediatr Ophthalmol Strabismus. 2008;45(1):51–4.
Parikh S, Swaiman KF, Kim Y. Neurologic characteristics of childhood lupus erythematosus. Pediatr Neurol. 1995;13(3):198–201.
Quintero-Del-Rio AI, Van M. Neurologic symptoms in children with systemic lupus erythematosus. J Child Neurol. 2000;15(12):803–7.
Genevay S, Hayem G, Hamza S, Palazzo E, Meyer O, Kahn MF. Oculomotor palsy in six patients with systemic lupus erythematosus. A possible role of antiphospholipid syndrome. Lupus. 2002;11(5):313–6.
Liao CH, Yang YH, Chiang BL. Systemic lupus erythematosus with presentation as vertigo and vertical nystagmus: report of one case. Acta Paediatr Taiwan. 2003;44(3):158–60.
Georgakopoulos CD, Kargiotis O, Eliopoulou MI, Makri OE, Exarchou AM, Papathanasopoulos P. Diplopia due to systemic lupus erythematosus in a child: a rare clinical presenting sign of the disease. J Child Neurol. 2011;26(12):1576–9.
Koch M, Langmann A. Diplopia as the presenting sign of systemic lupus erythematosus: the chameleon diagnosis. J AAPOS. 2006;10(2):184–5.
Steinlin MI, Blaser SI, Gilday DL, Eddy AA, Logan WJ, Laxer RM, et al. Neurologic manifestations of pediatric systemic lupus erythematosus. Pediatr Neurol. 1995;13(3):191–7.
Vachvanichsanong P, Dissaneewate P, Vasikananont P. Pseudotumor cerebri in a boy with systemic lupus erythematosus. Am J Dis Child. 1992;146(12):1417–9.
Ahmadieh H, Roodpeyma S, Azarmina M, Soheilian M, Sajjadi SH. Bilateral simultaneous optic neuritis in childhood systemic lupus erythematosus. A case report. J Neuroophthalmol. 1994;14(2):84–6.
Honda Y. Scintillating scotoma as the first symptom of systemic lupus erythematosus. Metab Pediatr Syst Ophthalmol. 1987;10(1):22–3.
Ushiyama O, Ushiyama K, Koarada S, Tada Y, Suzuki N, Ohta A, et al. Retinal disease in patients with systemic lupus erythematosus. Ann Rheum Dis. 2000;59(9):705–8.
Durrani OM, Gordon C, Murray PI. Primary anti-phospholipid antibody syndrome (APS): current concepts. Surv Ophthalmol. 2002;47(3):215–38.
Sivaraj RR, Durrani OM, Denniston AK, Murray PI, Gordon C. Ocular manifestations of systemic lupus erythematosus. Rheumatology (Oxford). 2007;46(12):1757–62.
Clifton F, Greer CH. Ocular changes in acute systemic lupus erythematosus. Br J Ophthalmol. 1955;39(1):1–10.
Lanham JG, Barrie T, Kohner EM, Hughes GR. SLE retinopathy: evaluation by fluorescein angiography. Ann Rheum Dis. 1982;41(5):473–8.
Coppeto J, Lessell S. Retinopathy in systemic lupus erythematosus. Arch Ophthalmol. 1977;95(5):794–7.
Graham EM, Spalton DJ, Barnard RO, Garner A, Russell RW. Cerebral and retinal vascular changes in systemic lupus erythematosus. Ophthalmology. 1985;92(3):444–8.
Vine AK, Barr CC. Proliferative lupus retinopathy. Arch Ophthalmol. 1984;102(6):852–4.
Jabs DA, Fine SL, Hochberg MC, Newman SA, Heiner GG, Stevens MB. Severe retinal vaso-occlusive disease in systemic lupus erythematous. Arch Ophthalmol. 1986;104(4):558–63.
Aristodemou P, Stanford M. Therapy insight: the recognition and treatment of retinal manifestations of systemic vasculitis. Nat Clin Pract Rheumatol. 2006;2(8):443–51.
Au A, O’Day J. Review of severe vaso-occlusive retinopathy in systemic lupus erythematosus and the antiphospholipid syndrome: associations, visual outcomes, complications and treatment. Clin Experiment Ophthalmol. 2004;32(1):87–100.
Cook CD, Wedgwood RJ, Craig JM, Hartmann JR, Janeway CA. Systemic lupus erythematosus. Description of 37 cases in children and a discussion of endocrine therapy in 32 of the cases. Pediatrics. 1960;26:570–85.
Ho TY, Chung YM, Lee AF, Tsai CY. Severe vaso-occlusive retinopathy as the primary manifestation in a patient with systemic lupus erythematosus. J Chin Med Assoc. 2008;71(7):377–80.
Appan S, Boey ML, Lim KW. Multiple thromboses in systemic lupus erythematosus. Arch Dis Child. 1987;62(7):739–41.
Montehermoso A, Cervera R, Font J, Ramos-Casals M, Garcia-carrasco M, Formiga F, et al. Association of antiphospholipid antibodies with retinal vascular disease in systemic lupus erythematosus. Semin Arthritis Rheum. 1999;28(5):326–32.
Bandyopadhyay SK, Moulick A, Dutta A. Retinal vasculitis—an initial presentation of systemic lupus erythematosus. J Indian Med Assoc. 2006;104(9):526–7.
Rao VA, Pandian DG, Kasturi N, Muthukrishanan V, Thappa DM. A case to illustrate the role of ophthalmologist in systemic lupus erythematosus. Indian J Dermatol. 2010;55(3):268–70.
Nguyen QD, Uy HS, Akpek EK, Harper SL, Zacks DN, Foster CS. Choroidopathy of systemic lupus erythematosus. Lupus. 2000;9(4):288–98.
Lavina AM, Agarwal A, Hunyor A, Gass JD. Lupus choroidopathy and choroidal effusions. Retina. 2002;22(5):643–7.
Gharbiya M, Bozzoni-Pantaleoni F, Augello F, Balacco-Gabrieli C. Indocyanine green angiographic findings in systemic lupus erythematosus choroidopathy. Am J Ophthalmol. 2002;134(2):286–90.
Cunningham Jr ET, Alfred PR, Irvine AR. Central serous chorioretinopathy in patients with systemic lupus erythematosus. Ophthalmology. 1996;103(12):2081–90.
Ravelli A, Di Fuccia G, Caporali R, Malvezzi F, Montecucco C, Martini A. Severe retinopathy in systemic lupus erythematosus associated with IgG anticardiolipin antibodies. Acta Paediatr. 1993;82(6–7):624–6.
Matsuo T, Nakayama T, Koyama T, Matsuo N. Multifocal pigment epithelial damages with serous retinal detachment in systemic lupus erythematosus. Ophthalmologica. 1987;195(2):97–102.
Gass JD. A fluorescein angiographic study of macular dysfunction secondary to retinal vascular disease. VI. X-ray irradiation, carotid artery occlusion, collagen vascular disease, and vitritis. Arch Ophthalmol. 1968;80(5):606–17.
Rynes RI. Antimalarial drugs in the treatment of rheumatological diseases. Br J Rheumatol. 1997;36(7):799–805.
Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis. 2010;69(1):20–8.
Percival SP, Meanock I. Chloroquine: ophthalmological safety, and clinical assessment in rheumatoid arthritis. Br Med J. 1968;3(5618):579–84.
Rynes RI, Krohel G, Falbo A, Reinecke RD, Wolfe B, Bartholomew LE. Ophthalmologic safety of long-term hydroxychloroquine treatment. Arthritis Rheum. 1979;22(8):832–6.
Grierson DJ. Hydroxychloroquine and visual screening in a rheumatology outpatient clinic. Ann Rheum Dis. 1997;56(3):188–90.
Kobak S, Deveci H. Retinopathy due to antimalarial drugs in patients with connective tissue diseases: are they so innocent? A single center retrospective study. Int J Rheum Dis. 2010;13(3):e11–5.
Yam JC, Kwok AK. Ocular toxicity of hydroxychloroquine. Hong Kong Med J. 2006;12(4):294–304.
Levy GD, Munz SJ, Paschal J, Cohen HB, Pince KJ, Peterson T. Incidence of hydroxychloroquine retinopathy in 1,207 patients in a large multicenter outpatient practice. Arthritis Rheum. 1997;40(8):1482–6.
Hollander DA, Aldave AJ. Drug-induced corneal complications. Curr Opin Ophthalmol. 2004;15(6):541–8.
Payne JF, Hubbard 3rd GB, Aaberg Sr TM, Yan J. Clinical characteristics of hydroxychloroquine retinopathy. Br J Ophthalmol. 2011;95(2):245–50.
Wolfe F, Marmor MF. Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res. 2010;62(6):775–84.
Marmor MF, Kellner U, Lai TY, Lyons JS, Mieler WF. American Academy of O. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology. 2011;118(2):415–22.
Michaelides M, Stover NB, Francis PJ, Weleber RG. Retinal toxicity associated with hydroxychloroquine and chloroquine: risk factors, screening, and progression despite cessation of therapy. Arch Ophthalmol. 2011;129(1):30–9.
Bernstein HN. Ophthalmologic considerations and testing in patients receiving long-term antimalarial therapy. Am J Med. 1983;75(1A):25–34.
Fraga MM, Len CA, dos Santos Finamor LP, Matos KT, Muccioli C, Hilario MO, et al. Ocular changes due to the treatment of juvenile systemic lupus erythematosus. Rev Bras Reumatol. 2011;51(6):554–7.
Marmor MF. Comparison of screening procedures in hydroxychloroquine toxicity. Arch Ophthalmol. 2012;130(4):461–9.
Silverman E, Eddy A. Systemic lupus erythematosus. In: Cassidy JT, editor. Textbook of pediatric rheumatology. 6th ed. Philadelphia: Saunders; 2011. p. 315–43.
Brunner HI, Klein-Gitelman MS, Ying J, Tucker LB, Silverman ED. Corticosteroid use in childhood-onset systemic lupus erythematosus-practice patterns at four pediatric rheumatology centers. Clin Exp Rheumatol. 2009;27(1):155–62.
Mina R, Brunner HI. Pediatric lupus—are there differences in presentation, genetics, response to therapy, and damage accrual compared with adult lupus? Rheum Dis Clin North Am. 2010;36(1):53–80, vii–viii.
Brunner HI, Gladman DD, Ibanez D, Urowitz MD, Silverman ED. Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus. Arthritis Rheum. 2008;58(2):556–62.
Brunner HI, Huggins J, Klein-Gitelman MS. Pediatric SLE—towards a comprehensive management plan. Nat Rev Rheumatol. 2011;7(4):225–33.
Caeiro F, Michielson FM, Bernstein R, Hughes GR, Ansell BM. Systemic lupus erythematosus in childhood. Ann Rheum Dis. 1981;40(4):325–31.
Lee SJ, Silverman E, Bargman JM. The role of antimalarial agents in the treatment of SLE and lupus nephritis. Nat Rev Nephrol. 2011;7(12):718–29.
Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med. 2005;353(21):2219–28.
Lo MS, Tsokos GC. Treatment of systemic lupus erythematosus: new advances in targeted therapy. Ann N Y Acad Sci. 2012;1247:138–52.
Jabs DA, Hanneken AM, Schachat AP, Fine SL. Choroidopathy in systemic lupus erythematosus. Arch Ophthalmol. 1988;106(2):230–4.
Chaine G, Haouat M, Menard-Molcard C, Favard C, Vignal-Clermont C, Campinchi-Tardy F, et al. Central serous chorioretinopathy and systemic steroid therapy. J Fr Ophtalmol. 2001;24(2):139–46.
Tarabishy AB, Ahn E, Mandell BF, Lowder CY. Central serous retinopathy. Arthritis Care Res. 2011;63(8):1075–82.
Khng CG, Yap EY, Au-Eong KG, Lim TH, Leong KH. Central serous retinopathy complicating systemic lupus erythematosus: a case series. Clin Experiment Ophthalmol. 2000;28(4):309–13.
Mavrikakis I, Sfikakis PP, Mavrikakis E, Rougas K, Nikolaou A, Kostopoulos C, et al. The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine: a reappraisal. Ophthalmology. 2003;110(7):1321–6.
Burgos-Vargas R. The juvenile-onset spondyloarthritides. Rheum Dis Clin North Am. 2002;28(3):531–60, vi.
Petty RE, Cassidy JT. Enthesitis-related arthritis (juveinel ankylosing spondylitis). In: Cassidy JT, editor. Textbook of pediatric rheumatology. 6th ed. Philadelphia: Saunders; 2011. p. 272–86.
Burgos-Vargas R, Pacheco-Tena C, Vazquez-Mellado J. Juvenile-onset spondyloarthropathies. Rheum Dis Clin North Am. 1997;23(3):569–98.
Rosenberg AM, Petty RE. A syndrome of seronegative enthesopathy and arthropathy in children. Arthritis Rheum. 1982;25(9):1041–7.
Kasapcopur O, Demirli N, Ozdogan H, Apelyan M, Caliskan S, Sever L, et al. Evaluation of classification criteria for juvenile-onset spondyloarthropathies. Rheumatol Int. 2005;25(6):414–8.
Cabral DA, Malleson PN, Petty RE. Spondyloarthropathies of childhood. Pediatr Clin North Am. 1995;42(5):1051–70.
van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27(4):361–8.
Amor B, Dougados M, Listrat V, Menkes CJ, Dubost JJ, Roux H, et al. Evaluation of the Amor criteria for spondylarthropathies and European Spondylarthropathy Study Group (ESSG). A cross-sectional analysis of 2,228 patients. Ann Med Interne. 1991;142(2):85–9.
Dougados M, van der Linden S, Juhlin R, Huitfeldt B, Amor B, Calin A, et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum. 1991;34(10):1218–27.
Colbert RA. Classification of juvenile spondyloarthritis: enthesitis-related arthritis and beyond. Nat Rev Rheumatol. 2010;6(8):477–85.
Tse SM, Laxer RM. New advances in juvenile spondyloarthritis. Nat Rev Rheumatol. 2012;8(5):269–79.
Stone M, Warren RW, Bruckel J, Cooper D, Cortinovis D, Inman RD. Juvenile-onset ankylosing spondylitis is associated with worse functional outcomes than adult-onset ankylosing spondylitis. Arthritis Rheum. 2005;53(3):445–51.
Gensler LS, Ward MM, Reveille JD, Learch TJ, Weisman MH, Davis Jr JC. Clinical, radiographic and functional differences between juvenile-onset and adult-onset ankylosing spondylitis: results from the PSOAS cohort. Ann Rheum Dis. 2008;67(2):233–7.
Ozgocmen S, Ardicoglu O, Kamanli A, Kaya A, Durmus B, Yildirim K, et al. Pattern of disease onset, diagnostic delay, and clinical features in juvenile onset and adult onset ankylosing spondylitis. J Rheumatol. 2009;36(12):2830–3.
Kingsley G, Sieper J. Third International Workshop on Reactive Arthritis. 23–26 September 1995, Berlin, Germany. Report and abstracts. Ann Rheum Dis. 1996;55(8):564–84.
Pacheco-Tena C, Alvarado De La Barrera C, Lopez-Vidal Y, Vazquez-Mellado J, Richaud-Patin Y, Amieva RI, et al. Bacterial DNA in synovial fluid cells of patients with juvenile onset spondyloarthropathies. Rheumatology (Oxford). 2001;40(8):920–7.
Raymond P. Les maladies de nos ancetres à l’ge de la pierre (The diseases of our ancestors in the stone age). Aesculape. 1912;2:121–3.
Ruffer MA, Rietta A. On osseous lesions in ancient Egyptians. J Pathol Bacteriol. 1912;16:439–65.
Short CL. The antiquity of rheumatoid arthritis. Arthritis Rheum. 1974;17(3):193–205.
Calin A. Ankylosing spondylitis and the spondylarthropathies. In: Schumacher Jr HR, Klippel JH, Koopman WJ, editors. Primer on the Rheumatic diseases. 9th ed. Atlanta: Arthritis Foundation; 1988.
Burgos-Vargas R, Vazquez-Mellado J, Gomez-Gordillo M, Katona G. Uveitis of juvenile ankylosing spondylitis. J Rheumatol. 1988;15(6):1039.
Schlosstein L, Terasaki PI, Bluestone R, Pearson CM. High association of an HL-A antigen, W27, with ankylosing spondylitis. N Engl J Med. 1973;288(14):704–6.
Brodie BC. Inflammation of the synovial membranes of joints. In: Longman, Hurst, Rees, Orme, Brown, editors. Pathological and surgical observations on diseases of the joints. London;1818. p. 6–63.
Stoll M (1776). Cited by Huette: de l’arthrite dysenterique. Arch Med Gen Trop. 1869;14:29–30.
Reiter H. Uber eine bisher unerkannate Spirochateninfektion (Spirochetosis arthritica). Dtsch Med Wochenschr. 1916;42:1535–6.
Junghanns O. Ein weiterer Fall von Urethritis nongonorrhoica und septischer Allgemeinerkrankung. Deutsche med Wchnschr. 1918;44:130.
Zewi M. Morbus reiteri. Acta Ophthalmol. 1947;25:47–60.
Harkness AH. Reiter’s syndrome. Br Med J. 1947;1(4504):611.
Brewerton DA, Caffrey M, Nicholls A, Walters D, James DC. Acute anterior uveitis and HL-A 27. Lancet. 1973;302(7836):994–6.
Panush RS, Paraschiv D, Dorff RE. The tainted legacy of Hans Reiter. Semin Arthritis Rheum. 2003;32(4):231–6.
Panush RS, Wallace DJ, Dorff RE, Engleman EP. Retraction of the suggestion to use the term “Reiter’s syndrome” sixty-five years later: the legacy of Reiter, a war criminal, should not be eponymic honor but rather condemnation. Arthritis Rheum. 2007;56(2):693–4.
Hofer M. Spondylarthropathies in children—are they different from those in adults? Best Pract Res Clin Rheumatol. 2006;20(2):315–28.
Oen K, Fast M, Postl B. Epidemiology of juvenile rheumatoid arthritis in Manitoba, Canada, 1975–92: cycles in incidence. J Rheumatol. 1995;22(4):745–50.
Denardo BA, Tucker LB, Miller LC, Szer IS, Schaller JG. Demography of a regional pediatric rheumatology patient population. Affiliated Children’s Arthritis Centers of New England. J Rheumatol. 1994;21(8):1553–61.
Gomez KS, Raza K, Jones SD, Kennedy LG, Calin A. Juvenile onset ankylosing spondylitis—more girls than we thought? J Rheumatol. 1997;24(4):735–7.
Bukulmez H, Colbert RA. Juvenile spondyloarthropathies and related arthritis. Curr Opin Rheumatol. 2002;14(5):531–5.
Burgos-Vargas R, Naranjo A, Castillo J, Katona G. Ankylosing spondylitis in the Mexican mestizo: patterns of disease according to age at onset. J Rheumatol. 1989;16(2):186–91.
Garcia-Morteo O, Maldonado-Cocco JA, Suarez-Almazor ME, Garay E. Ankylosing spondylitis of juvenile onset: comparison with adult onset disease. Scand J Rheumatol. 1983;12(3):246–8.
Prieur AM. Spondyloarthropathies in childhood. Baillieres Clin Rheumatol. 1998;12(2):287–307.
Burgos-Vargas R, Vazquez-Mellado J. The early clinical recognition of juvenile-onset ankylosing spondylitis and its differentiation from juvenile rheumatoid arthritis. Arthritis Rheum. 1995;38(6):835–44.
Jacobs JC, Berdon WE, Johnston AD. HLA-B27-associated spondyloarthritis and enthesopathy in childhood: clinical, pathologic, and radiographic observations in 58 patients. J Pediatr. 1982;100(4):521–8.
Olivieri I, Foto M, Ruju GP, Gemignani G, Giustarini S, Pasero G. Low frequency of axial involvement in Caucasian pediatric patients with seronegative enthesopathy and arthropathy syndrome after 5 years of disease. J Rheumatol. 1992;19(3):469–75.
Marks SH, Barnett M, Calin A. A case-control study of juvenile- and adult-onset ankylosing spondylitis. J Rheumatol. 1982;9(5):739–41.
Khan MA. Ankylosing spondylitis. New York: Oxford University Press; 2009.
Mielants H, Veys EM, Cuvelier C, De Vos M, Goemaere S, Maertens M, et al. Gut inflammation in children with late onset pauciarticular juvenile chronic arthritis and evolution to adult spondyloarthropathy—a prospective study. J Rheumatol. 1993;20(9):1567–72.
Mielants H, Veys EM, Goemaere S, Goethals K, Cuvelier C, De Vos M. Gut inflammation in the spondyloarthropathies: clinical, radiologic, biologic and genetic features in relation to the type of histology. A prospective study. J Rheumatol. 1991;18(10):1542–51.
Mielants H, Veys EM, Joos R, Cuvelier C, De Vos M, Proot F. Late onset pauciarticular juvenile chronic arthritis: relation to gut inflammation. J Rheumatol. 1987;14(3):459–65.
Ladd JR, Cassidy JT, Martel W. Juvenile ankylosing spondylitis. Arthritis Rheum. 1971;14(5):579–90.
Bywaters EG. Ankylosing spondylitis in childhood. Clin Rheum Dis. 1976;2:387–96.
Reid GD, Patterson MW, Patterson AC, Cooperberg PL. Aortic insufficiency in association with juvenile ankylosing spondylitis. J Pediatr. 1979;95(1):78–80.
Huppertz H, Voigt I, Muller-Scholden J, Sandhage K. Cardiac manifestations in patients with HLA B27-associated juvenile arthritis. Pediatr Cardiol. 2000;21(2):141–7.
Kim PS, Klausmeier TL, Orr DP. Reactive arthritis: a review. J Adolesc Health. 2009;44(4):309–15.
Hussein A. [Spectrum of post-enteritic reactive arthritis in childhood]. Monatsschr Kinderheilkund. 1987;135(2):93–8.
Burgos-Vargas R, Vazques-Mellado J. Reactive arthritis. In: Cassidy JT, Petty RE, Laxer RM, Lindsley CB, editors. Textbook of pediatric rheumatology. 6th ed. Philadelphia: Saunders; 2011. p. 591–9.
Kanakoudi-Tsakalidou F, Pardalos G, Pratsidou-Gertsi P, Kansouzidou-Kanakoudi A, Tsangaropoulou-Stinga H. Persistent or severe course of reactive arthritis following Salmonella enteritidis infection. A prospective study of 9 cases. Scand J Rheumatol. 1998;27(6):431–4.
Hoogkamp-Korstanje JA, Stolk-Engelaar VM. Yersinia enterocolitica infection in children. Pediatr Infect Dis J. 1995;14(9):771–5.
Leino R, Makela AL, Tiilikainen A, Toivanen A. Yersinia arthritis in children. Scand J Rheumatol. 1980;9(4):245–9.
Job-Deslandre C, Menkes CJ, Godran A, Amor B. Ankylosing spondylitis with juvenile onset. Study of 62 cases. Rev Rhum Mal Osteoartic. 1987;54(3):209–12.
O’Shea FD, Boyle E, Riarh R, Tse SM, Laxer RM, Inman RD. Comparison of clinical and radiographic severity of juvenile-onset versus adult-onset ankylosing spondylitis. Ann Rheum Dis. 2009;68(9):1407–12.
Kanski JJ, Shun-Shin GA. Systemic uveitis syndromes in childhood: an analysis of 340 cases. Ophthalmology. 1984;91(10):1247–52.
Loh AR, Acharya NR. Incidence rates and risk factors for ocular complications and vision loss in HLA-B27-associated uveitis. Am J Ophthalmol. 2010;150(4):534–42.e2.
Dodds EM, Lowder CY, Meisler DM. Posterior segment inflammation in HLA-B27+ acute anterior uveitis: clinical characteristics. Ocul Immunol Inflamm. 1999;7(2):85–92.
Rodriguez A, Akova YA, Pedroza-Seres M, Foster CS. Posterior segment ocular manifestations in patients with HLA-B27-associated uveitis. Ophthalmology. 1994;101(7):1267–74.
Bayen H, Bayen MC, De Curzon HP, Espinasse-Berrod MA, Manderieux N, Furia M, et al. Involvement of the posterior eye segment in HLA B27(+) iridocyclitis. Incidence. Value of surgical treatment. J Fr Ophtalmol. 1988;11(8–9):561–6.
Singsen BH, Bernstein BH, Koster-King KG, Glovsky MM, Hanson V. Reiter’s syndrome in childhood. Arthritis Rheum. 1977;20(2 Suppl):402–7.
Lockie GN, Hunder GG. Reiter’s syndrome in children. A case report and review. Arthritis Rheum. 1971;14(6):767–72.
Fox R, Calin A, Gerber RC, Gibson D. The chronicity of symptoms and disability in Reiter’s syndrome. An analysis of 131 consecutive patients. Ann Intern Med. 1979;91(2):190–3.
Saari KM, Vilppula A, Lassus A, Leirisalo M, Saari R. Ocular inflammation in Reiter’s disease after Salmonella enteritis. Am J Ophthalmol. 1980;90(1):63–8.
Davies NE, Haverty JR, Boatwright M. Reiter’s disease associated with shigellosis. South Med J. 1969;62(8):1011–4.
Florman AL, Goldstein HM. Arthritis, conjunctivitis, and urethritis, so-called Reiter’s syndrome, in a 4-year-old boy. J Pediatr. 1948;33(2):172–7.
Jacobs AG. A case of Reiter’s syndrome in childhood. Br Med J. 1961;2(5245):155.
Moss IS. Reiter’s Disease in Childhood. Br J Vener Dis. 1964;40:166–9.
Prutki M, Tambic Bukovac L, Jelusic M, Potocki K, Kralik M, Malcic I. Retrospective study of juvenile spondylarthropathies in Croatia over the last 11 years. Clin Exp Rheumatol. 2008;26(4):693–9.
Bollow M, Braun J, Biedermann T, Mutze S, Paris S, Schauer-Petrowskaja C, et al. Use of contrast-enhanced MR imaging to detect sacroiliitis in children. Skeletal Radiol. 1998;27(11):606–16.
Carter JD, Hudson AP. Reactive arthritis: clinical aspects and medical management. Rheum Dis Clin North Am. 2009;35(1):21–44.
Wanders A, Heijde D, Landewe R, Behier JM, Calin A, Olivieri I, et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum. 2005;52(6):1756–65.
Burgos-Vargas R, Vazquez-Mellado J, Pacheco-Tena C, Hernandez-Garduno A, Goycochea-Robles MV. A 26 week randomised, double blind, placebo controlled exploratory study of sulfasalazine in juvenile onset spondyloarthropathies. Ann Rheum Dis. 2002;61(10):941–2.
van Rossum MA, Fiselier TJ, Franssen MJ, Zwinderman AH, ten Cate R, van Suijlekom-Smit LW, et al. Sulfasalazine in the treatment of juvenile chronic arthritis: a randomized, double-blind, placebo-controlled, multicenter study. Dutch Juvenile Chronic Arthritis Study Group. Arthritis Rheum. 1998;41(5):808–16.
Tse SM, Burgos-Vargas R, Laxer RM. Anti-tumor necrosis factor alpha blockade in the treatment of juvenile spondylarthropathy. Arthritis Rheum. 2005;52(7):2103–8.
Schmeling H, Horneff G. Infliximab in two patients with juvenile ankylosing spondylitis. Rheumatol Int. 2004;24(3):173–6.
Sulpice M, Deslandre CJ, Quartier P. Efficacy and safety of TNFalpha antagonist therapy in patients with juvenile spondyloarthropathies. Joint Bone Spine. 2009;76(1):24–7.
Astrauskiene D. Efficacy of empirically prescribed amoxicillin and amoxicillin + clavulanic acid in children’s reactive arthritis: a randomised trial. Clin Exp Rheumatol. 2003;21(4):515–21.
Lee DA, Barker SM, Su WP, Allen GL, Liesegang TJ, Ilstrup DM. The clinical diagnosis of Reiter’s syndrome. Ophthalmic and nonophthalmic aspects. Ophthalmology. 1986;93(3):350–6.
Thadani SM, Foster CS. Treatment of ocular inflammation in children. Paediatr Drugs. 2004;6(5):289–301.
Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med. 2007;357(21):2153–65.
Yamamoto M, Sharma OP, Hosoda Y. Special report: the 1991 descriptive definition of sarcoidosis. Sardoidosis. 1992;9 Suppl 1:33–4.
Pattishall EN, Kendig Jr EL. Sarcoidosis in children. Pediatr Pulmonol. 1996;22(3):195–203.
Pattishall EN, Strope GL, Spinola SM, Denny FW. Childhood sarcoidosis. J Pediatr. 1986;108(2):169–77.
Hetherington S. Sarcoidosis in young children. Am J Dis Child. 1982;136(1):13–5.
Kendig Jr EL. Sarcoidosis in children: personal observations on age distribution. Pediatr Pulmonol. 1989;6(2):69–70.
Kanazawa N, Okafuji I, Kambe N, Nishikomori R, Nakata-Hizume M, Nagai S, et al. Early-onset sarcoidosis and CARD15 mutations with constitutive nuclear factor-kappaB activation: common genetic etiology with Blau syndrome. Blood. 2005;105(3):1195–7.
Rose CD, Wouters CH. Pediatric sarcoidosis. In: Cassidy JT, Petty RE, Laxer RM, Lindsley CB, editors. Textbook of pediatric rheumatology. Philadelphia: Saunders; 2011. p. 544–51.
Punzi L, Gava A, Galozzi P, Sfriso P. Miscellaneous non-inflammatory musculoskeletal conditions. Blau syndrome. Best Pract Res Clin Rheumatol. 2011;25(5):703–14.
Okafuji I, Nishikomori R, Kanazawa N, Kambe N, Fujisawa A, Yamazaki S, et al. Role of the NOD2 genotype in the clinical phenotype of Blau syndrome and early-onset sarcoidosis. Arthritis Rheum. 2009;60(1):242–50.
Rybicki BA, Iannuzzi MC, Frederick MM, Thompson BW, Rossman MD, Bresnitz EA, et al. Familial aggregation of sarcoidosis. A case-control etiologic study of sarcoidosis (ACCESS). Am J Respir Crit Care Med. 2001;164(11):2085–91.
Newman LS, Rose CS, Bresnitz EA, Rossman MD, Barnard J, Frederick M, et al. A case control etiologic study of sarcoidosis: environmental and occupational risk factors. Am J Respir Crit Care Med. 2004;170(12):1324–30.
Chen ES, Moller DR. Sarcoidosis—scientific progress and clinical challenges. Nat Rev Rheumatol. 2011;7(8):457–67.
Shetty AK, Gedalia A. Childhood sarcoidosis: a rare but fascinating disorder. Pediatr Rheum Online J. 2008;6:16.
Hutchinson J. Case of livid papillary psoriasis. In: Illustrations of clinical surgery. Vol 1. London: J and A Churchill; 1877. p. 42–3.
Boeck C. Multiple benign sarcoid of the skin. J Cutan Genitourinary Dis. 1899;17:543–50.
Kuznitsky E, Bittorf A. Sarkoid mit Beteiligung innerer Organe. Munch Med Wochenschr. 1915;62:1349–53.
McGovern JP, Merritt DH. Sarcoidosis in childhood. Adv Pediatr. 1956;8:97–135.
Hoffmann AL, Milman N, Byg KE. Childhood sarcoidosis in Denmark 1979–1994: incidence, clinical features and laboratory results at presentation in 48 children. Acta Paediatr. 2004;93(1):30–6.
Byg KE, Milman N, Hansen S. Sarcoidosis in Denmark 1980–1994. A registry-based incidence study comprising 5536 patients. Sarcoidosis Vasc Diffuse Lung Dis. 2003;20(1):46–52.
Hetherington SV. Sarcoidosis in children. Compr Ther. 1982;8(10):63–8.
Kendig Jr EL. The clinical picture of sarcoidosis in children. Pediatrics. 1974;54(3):289–92.
Narla LD, Hingsbergen EA, Jones JE. Adult diseases in children. Pediatr Radiol. 1999;29(4):244–54.
Rybicki BA, Maliarik MJ, Bock CH, Elston RC, Baughman RP, Kimani AP, et al. The Blau syndrome gene is not a major risk factor for sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 1999;16(2):203–8.
Rybicki BA, Iannuzzi MC. Epidemiology of sarcoidosis: recent advances and future prospects. Semin Respir Crit Care Med. 2007;28(1):22–35.
Hunninghake GW, Costabel U, Ando M, Baughman R, Cordier JF, du Bois R, et al. ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis Vasc Diffuse Lung Dis. 1999;16(2):149–73.
Lynch 3rd JP, Ma YL, Koss MN, White ES. Pulmonary sarcoidosis. Semin Respir Crit Care Med. 2007;28(1):53–74.
Merten DF, Kirks DR, Grossman H. Pulmonary sarcoidosis in childhood. AJR Am J Roentgenol. 1980;135(4):673–9.
Shetty AK, Gedalia A. Sarcoidosis in children. Curr Probl Pediatr. 2000;30(5):149–76.
Baculard A, Blanc N, Boule M, Fauroux B, Chadelat K, Boccon-Gibod L, et al. Pulmonary sarcoidosis in children: a follow-up study. Eur Respir J. 2001;17(4):628–35.
Pattishall EN, Strope GL, Denny FW. Pulmonary function in children with sarcoidosis. Am Rev Respir Dis. 1986;133(1):94–6.
Hafner R, Vogel P. Sarcoidosis of early onset. A challenge for the pediatric rheumatologist. Clin Exp Rheumatol. 1993;11(6):685–91.
Rosenberg AM, Yee EH, MacKenzie JW. Arthritis in childhood sarcoidosis. J Rheumatol. 1983;10(6):987–90.
Baumann RJ, Robertson Jr WC. Neurosarcoid presents differently in children than in adults. Pediatrics. 2003;112(6 Pt 1):e480–6.
Arostegui JI, Arnal C, Merino R, Modesto C, Antonia Carballo M, Moreno P, et al. NOD2 gene-associated pediatric granulomatous arthritis: clinical diversity, novel and recurrent mutations, and evidence of clinical improvement with interleukin-1 blockade in a Spanish cohort. Arthritis Rheum. 2007;56(11):3805–13.
Meiorin SM, Espada G, Costa CE, Tartara A, De Matteo E, Wouters C, et al. Granulomatous nephritis associated with R334Q mutation in NOD2. J Rheumatol. 2007;34(9):1945–7.
Becker ML, Martin TM, Doyle TM, Rose CD. Interstitial pneumonitis in Blau syndrome with documented mutation in CARD15. Arthritis Rheum. 2007;56(4):1292–4.
Crick RP, Hoyle C, Smellie H. The Eyes in Sarcoidosis. Br J Ophthalmol. 1961;45(7):461–81.
Obenauf CD, Shaw HE, Sydnor CF, Klintworth GK. Sarcoidosis and its ophthalmic manifestations. Am J Ophthalmol. 1978;86(5):648–55.
Jabs DA, Johns CJ. Ocular involvement in chronic sarcoidosis. Am J Ophthalmol. 1986;102(3):297–301.
Khanna A, Sidhu U, Bajwa G, Malhotra V. Pattern of ocular manifestations in patients with sarcoidosis in developing countries. Acta Ophthalmol Scand. 2007;85(6):609–12.
Bonfioli AA, Orefice F. Sarcoidosis. Semin Ophthalmol. 2005;20(3):177–82.
Bresnitz EA, Strom BL. Epidemiology of sarcoidosis. Epidemiol Rev. 1983;5:124–56.
Jasper PL, Denny FW. Sarcoidosis in children. With special emphasis on the natural history and treatment. J Pediatr. 1968;73(4):499–512.
Siltzbach LE, Greenberg GM. Childhood sarcoidosis—a study of 18 patients. N Engl J Med. 1968;279(23):1239–45.
Hoover DL, Khan JA, Giangiacomo J. Pediatric ocular sarcoidosis. Surv Ophthalmol. 1986;30(4):215–28.
Heinz C, Steuhl KP, Heiligenhaus A. Uveitis in childhood sarcoidosis. Klin Monbl Augenheilkd. 2005;222(4):348–52.
Kendig EL, Brummer DL. The prognosis of sarcoidosis in children. Chest. 1976;70(03):351–3.
Giles CL. Handleman. Panuveitis—presenting symptom of systemic sarcoidosis in a child. J Pediatr Ophthalmol. 1976;13(4):189–91.
Kataria S, Trevathan GE, Holland JE, Kataria YP. Ocular presentation of sarcoidosis in children. Clin Pediatr. 1983;22(12):793–7.
Khan JA, Hoover DL, Giangiacomo J, Singsen BH. Orbital and childhood sarcoidosis. J Pediatr Ophthalmol Strabismus. 1986;23(4):190–4.
Cohen KL, Peiffer Jr RL, Powell DA. Sarcoidosis and ocular disease in a young child. A case report and review of the literature. Arch Ophthalmol. 1981;99(3):422–4.
North Jr AF, Fink CW, Gibson WM, Levinson JE, Schuchter SL, Howard WK, et al. Sarcoid arthritis in children. Am J Med. 1970;48(4):449–55.
Toomey F, Bautista A. Rare manifestations of sarcoidosis in children. Radiology. 1970;94(3):569–73.
Kendig Jr EL, Peacock RL, Ryburn S. Sarcoidosis; report of three cases in siblings under fifteen years of age. N Engl J Med. 1959;260(19):962–6.
Lennarson P, Barney NP. Interstitial keratitis as presenting ophthalmic sign of sarcoidosis in a child. J Pediatr Ophthalmol Strabismus. 1995;32(3):194–6.
de Boer JH, Sijssens KM, Smeekens AE, Rothova A. Keratitis and arthritis in children with sarcoidosis. Br J Ophthalmol. 2009;93(6):835, 44.
Cohen DL. Sicca syndrome: an unusual manifestation of sarcoidosis in childhood. Am J Dis Child. 1983;137(3):289–90.
Latkany PA, Jabs DA, Smith JR, Rosenbaum JT, Tessler H, Schwab IR, et al. Multifocal choroiditis in patients with familial juvenile systemic granulomatosis. Am J Ophthalmol. 2002;134(6):897–904.
Kurokawa T, Kikuchi T, Ohta K, Imai H, Yoshimura N. Ocular manifestations in Blau syndrome associated with a CARD15/Nod2 mutation. Ophthalmology. 2003;110(10):2040–4.
Snyers B, Dahan K. Blau syndrome associated with a CARD15/NOD2 mutation. Am J Ophthalmol. 2006;142(6):1089–92.
Shetty AK, Gedalia A. Sarcoidosis: a pediatric perspective. Clin Pediatr. 1998;37(12):707–17.
Sokoloff L, Bunim JJ. Clinical and pathological studies of joint involvement in sarcoidosis. N Engl J Med. 1959;260(17):841–7.
Merritt JC, Lipper SL, Peiffer RL, Hale LM. Conjunctival biopsy in sarcoidosis. J Natl Med Assoc. 1980;72(4):347–9.
Lindsley CB, Petty RE. Overview and report on international registry of sarcoid arthritis in childhood. Curr Rheumatol Rep. 2000;2(4):343–8.
Milman N, Hoffmann AL, Byg KE. Sarcoidosis in children. Epidemiology in Danes, clinical features, diagnosis, treatment and prognosis. Acta Paediatr. 1998;87(8):871–8.
Sharma OP. Pulmonary sarcoidosis and corticosteroids. Am Rev Respir Dis. 1993;147(6 Pt 1):1598–600.
Baughman RP, Winget DB, Lower EE. Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial. Sarcoidosis Vasc Diffuse Lung Dis. 2000;17(1):60–6.
Chadelat K, Baculard A, Grimfeld A, Tournier G, Boule M, Boccon-Gibod L, et al. Pulmonary sarcoidosis in children: serial evaluation of bronchoalveolar lavage cells during corticosteroid treatment. Pediatr Pulmonol. 1993;16(1):41–7.
Webster GF, Razsi LK, Sanchez M, Shupack JL. Weekly low-dose methotrexate therapy for cutaneous sarcoidosis. J Am Acad Dermatol. 1991;24(3):451–4.
Kaye O, Palazzo E, Grossin M, Bourgeois P, Kahn MF, Malaise MG. Low-dose methotrexate: an effective corticosteroid-sparing agent in the musculoskeletal manifestations of sarcoidosis. Br J Rheumatol. 1995;34(7):642–4.
Lower EE, Baughman RP. Prolonged use of methotrexate for sarcoidosis. Arch Intern Med. 1995;155(8):846–51.
Soriano FG, Caramelli P, Nitrini R, Rocha AS. Neurosarcoidosis: therapeutic success with methotrexate. Postgrad Med J. 1990;66(772):142–3.
Milman N, Andersen CB, Hansen A, van Overeem Hansen T, Nielsen FC, Fledelius H, et al. Favourable effect of TNF-alpha inhibitor (infliximab) on Blau syndrome in monozygotic twins with a de novo CARD15 mutation. Acta Pathol Microbiol Immunol Scand. 2006;114(12):912–9.
Rose CD, Wouters CH, Meiorin S, Doyle TM, Davey MP, Rosenbaum JT, et al. Pediatric granulomatous arthritis: an international registry. Arthritis Rheum. 2006;54(10):3337–44.
Breinin GM, Devoe AG. Chelation of calcium with edathamil calcium-disodium in band keratopathy and corneal calcium affections. AMA Arch Ophthalmol. 1954;52(6):846–51.
Najjar DM, Cohen EJ, Rapuano CJ, Laibson PR. EDTA chelation for calcific band keratopathy: results and long-term follow-up. Am J Ophthalmol. 2004;137(6):1056–64.
Diamond JG, Kaplan HJ. Lensectomy and vitrectomy for complicated cataract secondary to uveitis. Arch Ophthalmol. 1978;96(10):1798–804.
Wedderburn LR, Rider LG. Juvenile dermatomyositis: new developments in pathogenesis, assessment and treatment. Best Pract Res Clin Rheumatol. 2009;23(5):665–78.
Pachman LM. Juvenile dermatomyositis. Pediatr Clin North Am. 1986;33(5):1097–117.
Ramanan AV, Feldman BM. Clinical features and outcomes of juvenile dermatomyositis and other childhood onset myositis syndromes. Rheum Dis Clin North Am. 2002;28(4):833–57.
Stringer E, Singh-Grewal D, Feldman BM. Predicting the course of juvenile dermatomyositis: significance of early clinical and laboratory features. Arthritis Rheum. 2008;58(11):3585–92.
Constantin T, Ponyi A, Orban I, Molnar K, Derfalvi B, Dicso F, et al. National registry of patients with juvenile idiopathic inflammatory myopathies in Hungary—clinical characteristics and disease course of 44 patients with juvenile dermatomyositis. Autoimmunity. 2006;39(3):223–32.
Spencer CH, Hanson V, Singsen BH, Bernstein BH, Kornreich HK, King KK. Course of treated juvenile dermatomyositis. J Pediatr. 1984;105(3):399–408.
Robinson AB, Reed AM. Clinical features, pathogenesis and treatment of juvenile and adult dermatomyositis. Nat Rev Rheumatol. 2011;7(11):664–75.
Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292(7):344–7.
Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975;292(8):403–7.
Brown VE, Pilkington CA, Feldman BM, Davidson JE. Network for Juvenile dermatomyositis PRES. An international consensus survey of the diagnostic criteria for juvenile dermatomyositis (JDM). Rheumatology (Oxford). 2006;45(8):990–3.
Jackson H. Myositis universalis acuta infectiosa, with a case. Boston Med Surg J. 1887;116:498.
Hepp P. Uber einen Fall von acuter parenchymatoser myositis, welche Geschwulste bildete und Fluctuation vortauschte. Klin Wochenschr. 1887;24:389.
Unverricht H. Uber eine eigentumliche Form von acuter Muskelentzundung mit einem der Trichinose ahnelnden Krankheitsbilde. Munch Med Wochenschr. 1887;34.
Wagner E. Ein Fall von acuter Polymyositis. Dtsch Arch Lin Med. 1887;40:241–66.
Batten FE. Dermato-myositis in a child, with pathological report. Proc R Soc Med. 1912;5:103–14.
Bruce GM. Retinitis in Dermatomyositis. Trans Am Ophthalmol Soc. 1938;36:282–97.
Mendez EP, Lipton R, Ramsey-Goldman R, Roettcher P, Bowyer S, Dyer A, et al. US incidence of juvenile dermatomyositis, 1995–1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry. Arthritis Rheum. 2003;49(3):300–5.
Symmons DP, Sills JA, Davis SM. The incidence of juvenile dermatomyositis: results from a nation-wide study. Br J Rheumatol. 1995;34(8):732–6.
McCann LJ, Juggins AD, Maillard SM, Wedderburn LR, Davidson JE, Murray KJ, et al. The Juvenile Dermatomyositis National Registry and Repository (UK and Ireland)—clinical characteristics of children recruited within the first 5 yr. Rheumatology (Oxford). 2006;45(10):1255–60.
Pachman LM, Lipton R, Ramsey-Goldman R, Shamiyeh E, Abbott K, Mendez EP, et al. History of infection before the onset of juvenile dermatomyositis: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Research Registry. Arthritis Rheum. 2005;53(2):166–72.
Hanson V, Kornreich H. Systemic rheumatic disorders (“collagen disease”) in childhood: lupus erythematosus, anaphylactoid purpura, dermatomyositis, and scleroderma. II. Bull Rheum Dis. 1967;17(6):441–6 concd.
Hanson V, Kornreich H. Systemic rheumatic disorders (“collagen disease”) in childhood: lupus erythematosus, anaphylactoid purpura, dermatomyositis, and scleroderma. I. Bull Rheum Dis. 1967;17(5):435–40 contd.
Huber AM. Idiopathic inflammatory myopathies in childhood: current concepts. Pediatr Clin North Am. 2012;59(2):365–80.
Rider LG, Lindsley CB, Cassidy JT. Juvenile dermatomyositis. In: Cassidy JT, Petty RE, Laxer RM, Lindsley CB, editors. Textbook of pediatric rheumatology. Philadelphia: Saunders; 2011. p. 375–413.
Pope E, Janson A, Khambalia A, Feldman B. Childhood acquired lipodystrophy: a retrospective study. J Am Acad Dermatol. 2006;55(6):947–50.
Huemer C, Kitson H, Malleson PN, Sanderson S, Huemer M, Cabral DA, et al. Lipodystrophy in patients with juvenile dermatomyositis—evaluation of clinical and metabolic abnormalities. J Rheumatol. 2001;28(3):610–5.
Verma S, Singh S, Bhalla AK, Khullar M. Study of subcutaneous fat in children with juvenile dermatomyositis. Arthritis Rheum. 2006;55(4):564–8.
Tse S, Lubelsky S, Gordon M, Al Mayouf SM, Babyn PS, Laxer RM, et al. The arthritis of inflammatory childhood myositis syndromes. J Rheumatol. 2001;28(1):192–7.
Mamyrova G, Kleiner DE, James-Newton L, Shaham B, Miller FW, Rider LG. Late-onset gastrointestinal pain in juvenile dermatomyositis as a manifestation of ischemic ulceration from chronic endarteropathy. Arthritis Rheum. 2007;57(5):881–4.
Feldman BM, Rider LG, Reed AM, Pachman LM. Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. Lancet. 2008;371(9631):2201–12.
Rouster-Stevens KA, Gursahaney A, Ngai KL, Daru JA, Pachman LM. Pharmacokinetic study of oral prednisolone compared with intravenous methylprednisolone in patients with juvenile dermatomyositis. Arthritis Rheum. 2008;59(2):222–6.
Pachman LM, Cooke N. Juvenile dermatomyositis: a clinical and immunologic study. J Pediatr. 1980;96(2):226–34.
Trapani S, Camiciottoli G, Vierucci A, Pistolesi M, Falcini F. Pulmonary involvement in juvenile dermatomyositis: a two-year longitudinal study. Rheumatology (Oxford). 2001;40(2):216–20.
Schwartz T, Sanner H, Husebye T, Flato B, Sjaastad I. Cardiac dysfunction in juvenile dermatomyositis: a case-control study. Ann Rheum Dis. 2011;70(5):766–71.
Everett MA, Curtis AC. Dermatomyositis; a review of nineteen cases in adolescents and children. AMA Arch Int Med. 1957;100(1):70–6.
Taban M, Perry JD. Juvenile dermatomyositis presenting with periorbital edema. Ophthal Plast Reconstr Surg. 2006;22(5):393–5.
Akikusa JD, Tennankore DK, Levin AV, Feldman BM. Eye findings in patients with juvenile dermatomyositis. J Rheumatol. 2005;32(10):1986–91.
Fruman LS, Ragsdale CG, Sullivan DB, Petty RE. Retinopathy in juvenile dermatomyositis. J Pediatr. 1976;88(2):267–9.
Harrison SM, Frenkel M, Grossman BJ, Matalon R. Retinopathy in childhood dermatomyositis. Am J Ophthalmol. 1973;76(5):786–90.
Ansell BM. Juvenile dermatomyositis. Rheum Dis Clin North Am. 1991;17(4):931–42.
Young TA, Al-Mayouf S, Feldman BM, Levin AV. Clinical assessment of conjunctival and episcleral vessel tortuosity in juvenile dermatomyositis. J AAPOS. 2002;6(4):238–40.
van Nouhuys CE, Sengers RC. Bilateral avascular zones of the conjunctiva in a patient with juvenile dermatomyositis. Am J Ophthalmol. 1987;104(4):440–2.
Sammartino A, Lucariello A, Esposito L, Vetrano A, Loffredo A. A rate presentation of bilateral membranous conjunctivitis in dermatomyositis. Ophthalmologica. 1982;184(2):97–102.
Cohen BH, Sedwick LA, Burde RM. Retinopathy of dermatomyositis. J Clin Neuroophthalmol. 1985;5(3):177–9.
Henkind P, Gold DH. Ocular manifestations of rheumatic disorders. Natural and iatrogenic. Rheumatology. 1973;4:13–59.
Bitnum S, Daeschner Jr CW, Travis LB, Dodge WF, Hopps HC. Dermatomyositis. J Pediatr. 1964;64:101–31.
Nutt AB. Late fundus changes in a case of acute dermatomyositis. Proc Roy Soc Med. 1951;44:979.
Liebman S, Cook C. Retinopathy with dermatomyositis. Arch Ophthalmol. 1965;74:704–5.
Munro S. Fundus appearances in a case of acute dermatomyositis. Br J Ophthalmol. 1959;43:548–58.
Lisman JV. Dermatomyositis with retinopathy; report of a case. Arch Ophthalmol. 1947;37:155–9.
Backhouse O, Griffiths B, Henderson T, Emery P. Ophthalmic manifestations of dermatomyositis. Ann Rheum Dis. 1998;57(8):447–9.
Stringer E, Bohnsack J, Bowyer SL, Griffin TA, Huber AM, Lang B, et al. Treatment approaches to juvenile dermatomyositis (JDM) across North America: the Childhood Arthritis and Rheumatology Research Alliance (CARRA) JDM Treatment Survey. J Rheumatol. 2010;37(9):1953–61.
Huber AM, Giannini EH, Bowyer SL, Kim S, Lang B, Lindsley CB, et al. Protocols for the initial treatment of moderately severe juvenile dermatomyositis: results of a Children’s Arthritis and Rheumatology Research Alliance Consensus Conference. Arthritis Care Res. 2010;62(2):219–25.
Huber AM, Robinson AB, Reed AM, Abramson L, Bout-Tabaku S, Carrasco R, et al. Consensus treatments for moderate juvenile dermatomyositis: beyond the first two months. Results of the second Childhood Arthritis and Rheumatology Research Alliance consensus conference. Arthritis Care Res. 2012;64(4):546–53.
Jabs DA, Mudun A, Dunn JP, Marsh MJ. Episcleritis and scleritis: clinical features and treatment results. Am J Ophthalmol. 2000;130(4):469–76.
Rabinovich CE. Challenges in the diagnosis and treatment of juvenile systemic sclerosis. Nat Rev Rheumatol. 2011;7(11): 676–80.
Herrick AL, Ennis H, Bhushan M, Silman AJ, Baildam EM. Clinical features of childhood localized scleroderma in an incidence cohort. Rheumatology (Oxford). 2011;50(10):1865–8.
Herrick AL, Ennis H, Bhushan M, Silman AJ, Baildam EM. Incidence of childhood linear scleroderma and systemic sclerosis in the UK and Ireland. Arthritis Care Res. 2010;62(2):213–8.
Gu YS, Kong J, Cheema GS, Keen CL, Wick G, Gershwin ME. The immunobiology of systemic sclerosis. Semin Arthritis Rheum. 2008;38(2):132–60.
Torok KS. Pediatric scleroderma: systemic or localized forms. Pediatr Clin North Am. 2012;59(2):381–405.
Peterson LS, Nelson AM, Su WP. Classification of morphea (localized scleroderma). Mayo Clin Proc. 1995;70(11):1068–76.
Zulian F. Systemic sclerosis and localized scleroderma in childhood. Rheum Dis Clin North Am. 2008;34(1):239–55, ix.
Laxer RM, Zulian F. Localized scleroderma. Curr Opin Rheumatol. 2006;18(6):606–13.
Zulian F, Woo P, Athreya BH, Laxer RM, Medsger Jr TA, Lehman TJ, et al. The Pediatric Rheumatology European Society/American College of Rheumatology/European League against Rheumatism provisional classification criteria for juvenile systemic sclerosis. Arthritis Rheum. 2007;57(2):203–12.
Curzio C. Discussioni anatomico-pratiche di un raro e stravagante morbo cutaneo in una giovane donna, felicemente curato in questo grande, Ospedale degl' Incurabili, indirizzate dal chiarissimo signor abate Nollet. Naples: Presso Giovanni di Simone; 1753.
Fantonetti G. Case of general induration fo the skin. Dublin J Med Sci. 1838;13:158–9.
Stucchi CA, Geiser JD. [Eye manifestations of generalized scleroderma. (Aspects in common with Sjogren's Syndrome)]. Doc Ophthalmol. 1967;22:72–110.
Scalapino K, Arkachaisri T, Lucas M, Fertig N, Helfrich DJ, Londino Jr AV, et al. Childhood onset systemic sclerosis: classification, clinical and serologic features, and survival in comparison with adult onset disease. J Rheumatol. 2006;33(5):1004–13.
Peterson LS, Nelson AM, Su WP, Mason T, O’Fallon WM, Gabriel SE. The epidemiology of morphea (localized scleroderma) in Olmsted County 1960–1993. J Rheumatol. 1997;24(1):73–80.
Pelkonen PM, Jalanko HJ, Lantto RK, Makela AL, Pietikainen MA, Savolainen HA, et al. Incidence of systemic connective tissue diseases in children: a nationwide prospective study in Finland. J Rheumatol. 1994;21(11):2143–6.
Martini G, Foeldvari I, Russo R, Cuttica R, Eberhard A, Ravelli A, et al. Systemic sclerosis in childhood: clinical and immunologic features of 153 patients in an international database. Arthritis Rheum. 2006;54(12):3971–8.
Christen-Zaech S, Hakim MD, Afsar FS, Paller AS. Pediatric morphea (localized scleroderma): review of 136 patients. J Am Acad Dermatol. 2008;59(3):385–96.
Zulian F, Athreya BH, Laxer R, Nelson AM, Feitosa de Oliveira SK, Punaro MG, et al. Juvenile localized scleroderma: clinical and epidemiological features in 750 children. An international study. Rheumatology (Oxford). 2006;45(5):614–20.
Foeldvari I, Zhavania M, Birdi N, Cuttica RJ, de Oliveira SH, Dent PB, et al. Favourable outcome in 135 children with juvenile systemic sclerosis: results of a multi-national survey. Rheumatology (Oxford). 2000;39(5):556–9.
Singsen BH. Scleroderma in childhood. Pediatr Clin North Am. 1986;33(5):1119–39.
Tollefson MM, Witman PM. En coup de sabre morphea and Parry-Romberg syndrome: a retrospective review of 54 patients. J Am Acad Dermatol. 2007;56(2):257–63.
Orozco-Covarrubias L, Guzman-Meza A, Ridaura-Sanz C, Carrasco Daza D, Sosa-de-Martinez C, Ruiz-Maldonado R. Scleroderma ‘en coup de sabre’ and progressive facial hemiatrophy. Is it possible to differentiate them? J Eur Acad Dermatol Venereol. 2002;16(4):361–6.
Lehman TJ. The Parry Romberg syndrome of progressive facial hemiatrophy and linear scleroderma en coup de sabre. Mistaken diagnosis or overlapping conditions? J Rheumatol. 1992;19(6):844–5.
Blaszczyk M, Krolicki L, Krasu M, Glinska O, Jablonska S. Progressive facial hemiatrophy: central nervous system involvement and relationship with scleroderma en coup de sabre. J Rheumatol. 2003;30(9):1997–2004.
Kister I, Inglese M, Laxer RM, Herbert J. Neurologic manifestations of localized scleroderma: a case report and literature review. Neurology. 2008;71(19):1538–45.
Medsger Jr TA. Natural history of systemic sclerosis and the assessment of disease activity, severity, functional status, and psychologic well-being. Rheum Dis Clin North Am. 2003;29(2):255–73, vi.
Rodnan GP, Medsger TA. The rheumatic manifestaions of progressive systemic sclerosis (scleroderma). Clin Orthop Relat Res. 1968;57:81–93.
Tailor R, Gupta A, Herrick A, Kwartz J. Ocular manifestations of scleroderma. Surv Ophthalmol. 2009;54(2):292–304.
Alarcon-Segovia D, Ibanez G, Hernandez-Ortiz J, Velazquez-Forero F, Gonzalez-Jimenez Y. Sjogren’s syndrome in progressive systemic sclerosis (scleroderma). Am J Med. 1974;57(1):78–85.
Horan EC. Ophthalmic manifestations of progressive systemic sclerosis. Br J Ophthalmol. 1969;53(6):388–92.
Kirkham TH. Scleroderma and Sjogren’s syndrome. Br J Ophthalmol. 1969;53(2):131–3.
West RH, Barnett AJ. Ocular involvement in scleroderma. Br J Ophthalmol. 1979;63(12):845–7.
Serup L, Serup J, Hagdrup HK. Increased central cornea thickness in systemic sclerosis. Acta Ophthalmol. 1984;62(1):69–74.
Agatston HJ. Scleroderma with retinopathy. Am J Ophthalmol. 1953;36(1):120–1.
Ashton N, Coomes EN, Garner A, Oliver DO. Retinopathy due to progressive systemic sclerosis. J Pathol Bacteriol. 1968;96(2):259–68.
Chan AY, Liu DT. Increased prevalence of ocular glaucomatous abnormalities in systemic sclerosis. Ann Rheum Dis. 2005;64(2):341–2; author reply 2.
Kitsos G, Tsifetaki N, Gorezis S, Drosos AA. Glaucomatous type abnormalities in patients with systemic sclerosis. Clin Exp Rheumatol. 2007;25(2):341.
Zannin ME, Martini G, Athreya BH, Russo R, Higgins G, Vittadello F, et al. Ocular involvement in children with localised scleroderma: a multi-centre study. Br J Ophthalmol. 2007;91(10):1311–4.
Muchnick RS, Aston SJ, Rees TD. Ocular manifestations and treatment of hemifacial atrophy. Am J Ophthalmol. 1979;88(5):889–97.
Miller MT, Sloane H, Goldberg MF, Grisolano J, Frenkel M, Mafee MF. Progressive hemifacial atrophy (Parry-Romberg disease). J Pediatr Ophthalmol Strabismus. 1987;24(1):27–36.
Ong K, Billson FA, Pathirana DS, Clifton-Bligh P. A case of progressive hemifacial atrophy with uveitis and retinal vasculitis. Aust N Z J Ophthalmol. 1991;19(4):295–8.
Roulez FM, Dangoisse C, Dufour D, Meire FM. Orbital myositis in a child with linear scleroderma en coup de sabre. J Pediatr Ophthalmol Strabismus. 2007;44(5):264–6.
Kee C, Hwang JM. Parry-Romberg syndrome presenting with recurrent exotropia and torticollis. J Pediatr Ophthalmol Strabismus. 2008;45(6):368–70.
Li SC, Feldman BM, Higgins GC, Haines KA, Punaro MG, O’Neil KM. Treatment of pediatric localized scleroderma: results of a survey of North American pediatric rheumatologists. J Rheumatol. 2010;37(1):175–81.
Torok KS, Arkachaisri T. Methotrexate and corticosteroids in the treatment of localized scleroderma: a standardized prospective longitudinal single-center study. J Rheumatol. 2012;39(2):286–94.
Uziel Y, Feldman BM, Krafchik BR, Yeung RS, Laxer RM. Methotrexate and corticosteroid therapy for pediatric localized scleroderma. J Pediatr. 2000;136(1):91–5.
Weibel L, Sampaio MC, Visentin MT, Howell KJ, Woo P, Harper JI. Evaluation of methotrexate and corticosteroids for the treatment of localized scleroderma (morphoea) in children. Br J Dermatol. 2006;155(5):1013–20.
Zulian F, Martini G, Vallongo C, Vittadello F, Falcini F, Patrizi A, et al. Methotrexate treatment in juvenile localized scleroderma: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2011;63(7):1998–2006.
Kowal-Bielecka O, Landewe R, Avouac J, Chwiesko S, Miniati I, Czirjak L, et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis. 2009;68(5):620–8.
Mouthon L, Berezne A, Guillevin L, Valeyre D. Therapeutic options for systemic sclerosis related interstitial lung diseases. Respir Med. 2010;104 Suppl 1:S59–69.
Abhishek A, Yazdani R, Pearce F, Regan M, Lim K, Hubbard R, et al. Outcome of systemic sclerosis associated interstitial lung disease treated with intravenous cyclophosphamide. Clin Rheumatol. 2011;30(8):1099–104.
Au K, Khanna D, Clements PJ, Furst DE, Tashkin DP. Current concepts in disease-modifying therapy for systemic sclerosis-associated interstitial lung disease: lessons from clinical trials. Curr Rheumatol Rep. 2009;11(2):111–9.
Gardner-Medwin JM, Dolezalova P, Cummins C, Southwood TR. Incidence of Henoch-Schonlein purpura, Kawasaki disease, and rare vasculitides in children of different ethnic origins. Lancet. 2002;360(9341):1197–202.
Saulsbury FT. Clinical update: Henoch-Schonlein purpura. Lancet. 2007;369(9566):976–8.
Saulsbury FT. Henoch-Schonlein purpura. Curr Opin Rheumatol. 2010;22(5):598–602.
Weiss PF, Klink AJ, Luan X, Feudtner C. Temporal association of Streptococcus, Staphylococcus, and parainfluenza pediatric hospitalizations and hospitalized cases of Henoch-Schonlein purpura. J Rheumatol. 2010;37(12):2587–94.
Atkinson SR, Barker DJ. Seasonal distribution of Henoch-Schonlein purpura. Br J Prev Soc Med. 1976;30(1):22–5.
Farley TA, Gillespie S, Rasoulpour M, Tolentino N, Hadler JL, Hurwitz E. Epidemiology of a cluster of Henoch-Schonlein purpura. Am J Dis Child. 1989;143(7):798–803.
Levy M, Broyer M, Arsan A, Levy-Bentolila D, Habib R. Anaphylactoid purpura nephritis in childhood: natural history and immunopathology. Adv Nephrol Necker Hosp. 1976;6:183–228.
Masuda M, Nakanishi K, Yoshizawa N, Iijima K, Yoshikawa N. Group A streptococcal antigen in the glomeruli of children with Henoch-Schonlein nephritis. Am J Kidney Dis. 2003;41(2):366–70.
Allen DM, Diamond LK, Howell DA. Anaphylactoid purpura in children (Schonlein-Henoch syndrome): review with a follow-up of the renal complications. AMA J Dis Child. 1960;99:833–54.
al-Sheyyab M, Batieha A, el-Shanti H, Daoud A. Henoch-Schonlein purpura and streptococcal infection: a prospective case-control study. Ann Trop Paediatr. 1999;19(3):253–5.
Minohara Y. [Studies on the relationship between anaphylactoid purpura and human parvovirus B19]. Kansenshogaku Zasshi. 1995;69(8):928–33.
Watanabe T, Oda Y. Henoch-Schonlein purpura nephritis associated with human parvovirus B19 infection. Pediatr Int. 2000;42(1):94–6.
Eisenstein EM. Lack of evidence for herpesvirus, retrovirus, or parvovirus infection in Henoch-Schonlein purpura. Clin Exp Rheumatol. 2002;20(5):734.
Heegaard ED, Taaning EB. Parvovirus B19 and parvovirus V9 are not associated with Henoch-Schonlein purpura in children. Pediatr Infect Dis J. 2002;21(1):31–4.
Liew SW, Kessel I. Letter: Mycoplasmal pneumonia preceding Henoch-Schonlein purpura. Arch Dis Child. 1974;49(11):912–3.
Kaneko K, Fujinaga S, Ohtomo Y, Nagaoka R, Obinata K, Yamashiro Y. Mycoplasma pneumoniae-associated Henoch-Schonlein purpura nephritis. Pediatr Nephrol. 1999;13(9):1000–1.
Trapani S, Micheli A, Grisolia F, Resti M, Chiappini E, Falcini F, et al. Henoch Schonlein purpura in childhood: epidemiological and clinical analysis of 150 cases over a 5-year period and review of literature. Semin Arthritis Rheum. 2005;35(3):143–53.
Calvino MC, Llorca J, Garcia-Porrua C, Fernandez-Iglesias JL, Rodriguez-Ledo P, Gonzalez-Gay MA. Henoch-Schonlein purpura in children from northwestern Spain: a 20-year epidemiologic and clinical study. Medicine. 2001;80(5):279–90.
Weiss PF. Pediatric vasculitis. Pediatr Clin North Am. 2012;59(2):407–23.
Gershoni-Baruch R, Broza Y, Brik R. Prevalence and significance of mutations in the familial Mediterranean fever gene in Henoch-Schonlein purpura. J Pediatr. 2003;143(5):658–61.
Stefansson Thors V, Kolka R, Sigurdardottir SL, Edvardsson VO, Arason G, Haraldsson A. Increased frequency of C4B*Q0 alleles in patients with Henoch-Schonlein purpura. Scand J Immunol. 2005;61(3):274–8.
Mills JA, Michel BA, Bloch DA, Calabrese LH, Hunder GG, Arend WP, et al. The American College of Rheumatology 1990 criteria for the classification of Henoch-Schonlein purpura. Arthritis Rheum. 1990;33(8):1114–21.
Ozen S, Pistorio A, Iusan SM, Bakkaloglu A, Herlin T, Brik R, et al. EULAR/PRINTO/PRES criteria for Henoch-Schonlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: final classification criteria. Ann Rheum Dis. 2010;69(5):798–806.
Heberden W. De purpureis maculis commentaries on the history and cure of diseases. London; 1802.
Schonlein JL. Allgemeine und specielle pathologie und therapie. 3rd ed. Hersau: Im Literatur-Comptoir; 1837.
Henoch EH. About a peculiar form of purpura, Berlin. Am J Dis Child. 1974;128(1):78–9.
Saulsbury FT. Henoch-Schonlein purpura in children. Report of 100 patients and review of the literature. Medicine. 1999;78(6):395–409.
Saulsbury FT. Epidemiology of Henoch-Schonlein purpura. Cleve Clin J Med. 2002;69 Suppl 2:SII87–9.
Stewart M, Savage JM, Bell B, McCord B. Long term renal prognosis of Henoch-Schonlein purpura in an unselected childhood population. Eur J Pediatr. 1988;147(2):113–5.
Ballinger S. Henoch-Schonlein purpura. Curr Opin Rheumatol. 2003;15(5):591–4.
Dedeoglu F, Sundel RP. Vasculitis in children. Pediatr Clin North Am. 2005;52(2):547–75, vii.
Chen SY, Kong MS. Gastrointestinal manifestations and complications of Henoch-Schonlein purpura. Chang Gung Med J. 2004;27(3):175–81.
Choong CK, Beasley SW. Intra-abdominal manifestations of Henoch-Schonlein purpura. J Paediatr Child Health. 1998;34(5):405–9.
Nathan K, Gunasekaran TS, Berman JH. Recurrent gastrointestinal Henoch-Schonlein purpura. J Clin Gastroenterol. 1999;29(1):86–9.
Brogan P, Bagga A. Leukocytoclastic vasculitis. In: Cassidy JT, Petty RE, Laxer RM, Lindsley CB, editors. Textbook of pediatric rheumatology. 6th ed. Philadelphia: Saunders; 2011. p. 483–97.
Meadow SR, Glasgow EF, White RH, Moncrieff MW, Cameron JS, Ogg CS. Schonlein-Henoch nephritis. Q J Med. 1972;41(163):241–58.
al-Sheyyab M, el-Shanti H, Ajlouni S, Batieha A, Daoud AS. Henoch-Schonlein purpura: clinical experience and contemplations on a streptococcal association. J Trop Pediatr. 1996;42(4):200–3.
Tizard EJ. Henoch-Schonlein purpura. Arch Dis Child. 1999;80(4):380–3.
Sahn DJ, Schwartz AD. Schonlein-Henoch syndrome: observations on some atypical clinical presentations. Pediatrics. 1972;49(4):614–6.
Ioannides AS, Turnock R. An audit of the management of the acute scrotum in children with Henoch-Schonlein Purpura. J R Coll Surg Edinb. 2001;46(2):98–9.
Lorentz Jr WB, Weaver RG. Eye involvement in anaphylactoid purpura. Am J Dis Child. 1980;134(5):524–5.
Barton CH, Vaziri ND. Central retinal vein occlusion associated with hemodialysis. Am J Med Sci. 1979;277(1):39–47.
Yamabe H, Ozawa K, Fukushi K, Kubota H, Ohsawa H, Akitsu H, et al. IgA nephropathy and Henoch-Schonlein purpura nephritis with anterior uveitis. Nephron. 1988;50(4):368–70.
Belman AL, Leicher CR, Moshe SL, Mezey AP. Neurologic manifestations of Schoenlein-Henoch purpura: report of three cases and review of the literature. Pediatrics. 1985;75(4):687–92.
Ryder HG, Marcus O. Henoch-Schonlein purpura: a case report. S Afr Med J. 1976;50(50):2005–6.
Ma’luf RN, Zein WM, El Dairi MA, Bashshur ZF. Bilateral subperiosteal orbital hematomas and Henoch-Schonlein purpura. Arch Ophthalmol. 2002;120(10):1398–9.
Wu TT, Sheu SJ, Chou LC, Wu TT, Sheu SJ, Sheu SJ. Henoch-Schonlein purpura with bilateral central retinal artery occlusion. Br J Ophthalmol. 2002;86(3):351–2.
Trygstad CW, Stiehm ER. Elevated serum IgA globulin in anaphylactoid purpura. Pediatrics. 1971;47(6):1023–8.
McCarthy HJ, Tizard EJ. Clinical practice: diagnosis and management of Henoch-Schonlein purpura. Eur J Pediatr. 2010;169(6):643–50.
Rosenblum ND, Winter HS. Steroid effects on the course of abdominal pain in children with Henoch-Schonlein purpura. Pediatrics. 1987;79(6):1018–21.
Szer IS. Gastrointestinal and renal involvement in vasculitis: management strategies in Henoch-Schonlein purpura. Cleve Clin J Med. 1999;66(5):312–7.
Wang L, Huang FC, Ko SF, Cheng MT. Successful treatment of mesenteric vasculitis caused by Henoch-Schonlein purpura with methylprednisolone pulse therapy. Clin Rheumatol. 2003;22(2):140–2.
Leung SP. Use of intravenous hydrocortisone in Henoch-Schonlein purpura. J Paediatr Child Health. 2001;37(3):309–10.
Jauhola O, Ronkainen J, Koskimies O, Ala-Houhala M, Arikoski P, Holtta T, et al. Renal manifestations of Henoch-Schonlein purpura in a 6-month prospective study of 223 children. Arch Dis Child. 2010;95(11):877–82.
Donnithorne KJ, Atkinson TP, Hinze CH, Nogueira JB, Saeed SA, Askenazi DJ, et al. Rituximab therapy for severe refractory chronic Henoch-Schonlein purpura. J Pediatr. 2009;155(1):136–9.
Cabral D, Benseler S. Granulomatous vasculitis, microscopic polyangiitis and primary angiitis of the central nervous system. In: Cassidy JT, Petty RE, Laxer RM, Lindsley CB, editors. Textbook of pediatric rheumatology. 6th ed. Philadelphia: Saunders; 2011. p. 521–43.
Akikusa JD, Schneider R, Harvey EA, Hebert D, Thorner PS, Laxer RM, et al. Clinical features and outcome of pediatric Wegener’s granulomatosis. Arthritis Rheum. 2007;57(5):837–44.
Feldman F, Fink H, Gruezo Z. Wegener’s granulomatosis. Report of a case in a 13-year-old girl. Am J Dis Child. 1966;112(6):587–92.
Falk RJ, Gross WL, Guillevin L, Hoffman G, Jayne DR, Jennette JC, et al. Granulomatosis with polyangiitis (Wegener’s): an alternative name for Wegener’s granulomatosis. J Am Soc Nephrol. 2011;22(4):587–8.
Falk RJ, Gross WL, Guillevin L, Hoffman G, Jayne DR, Jennette JC, et al. Granulomatosis with polyangiitis (Wegener’s): an alternative name for Wegener’s granulomatosis. Ann Rheum Dis. 2011;70(4):704.
Falk RJ, Gross WL, Guillevin L, Hoffman GS, Jayne DR, Jennette JC, et al. Granulomatosis with polyangiitis (Wegener’s): an alternative name for Wegener’s granulomatosis. Arthritis Rheum. 2011;63(4):863–4.
Leavitt RY, Fauci AS, Bloch DA, Michel BA, Hunder GG, Arend WP, et al. The American College of Rheumatology 1990 criteria for the classification of Wegener’s granulomatosis. Arthritis Rheum. 1990;33(8):1101–7.
Belostotsky VM, Shah V, Dillon MJ. Clinical features in 17 paediatric patients with Wegener granulomatosis. Pediatr Nephrol. 2002;17(9):754–61.
Ozen S, Ruperto N, Dillon MJ, Bagga A, Barron K, Davin JC, et al. EULAR/PReS endorsed consensus criteria for the classification of childhood vasculitides. Ann Rheum Dis. 2006;65(7):936–41.
Cabral DA, Uribe AG, Benseler S, O’Neil KM, Hashkes PJ, Higgins G, et al. Classification, presentation, and initial treatment of Wegener’s granulomatosis in childhood. Arthritis Rheum. 2009;60(11):3413–24.
McBride P. Case of rapid destruction of the nose and face. J Laryng Otol. 1897;12:64–6.
Klinger H. Grenzformen der periarteriitis nodosa. Frankf Z Pathol. 1931;42:455–80.
Harman LE, Margo CE. Wegener’s granulomatosis. Surv Ophthalmol. 1998;42(5):458–80.
Wegener F. Uber Generalisierte. Septische Gegasserkrankugen Verh Deutsch. 1936;29:202.
Wegener F. Ueber eine eigenartige rhinogene Granulomatose mit besonderer Beteiligung des Arteriensystems und der Nieren. Beitr Pathol Anat. 1939;102:30–68.
Godman GC, Churg J. Wegener’s granulomatosis: pathology and review of the literature. AMA Arch Pathol. 1954;58(6):533–53.
Rottem M, Fauci AS, Hallahan CW, Kerr GS, Lebovics R, Leavitt RY, et al. Wegener granulomatosis in children and adolescents: clinical presentation and outcome. J Pediatr. 1993;122(1):26–31.
Roback SA, Herdman RC, Hoyer J, Good RA. Wegener’s granulomatosis in a child. Observations on pathogenesis and treatment. Am J Dis Child. 1969;118(4):608–14.
Pakrou N, Selva D, Leibovitch I. Wegener’s granulomatosis: ophthalmic manifestations and management. Semin Arthritis Rheum. 2006;35(5):284–92.
Tarabishy AB, Schulte M, Papaliodis GN, Hoffman GS. Wegener’s granulomatosis: clinical manifestations, differential diagnosis, and management of ocular and systemic disease. Surv Ophthalmol. 2010;55(5):429–44.
Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med. 1992;116(6):488–98.
Bullen CL, Liesegang TJ, McDonald TJ, DeRemee RA. Ocular complications of Wegener’s granulomatosis. Ophthalmology. 1983;90(3):279–90.
Fauci AS, Haynes BF, Katz P, Wolff SM. Wegener’s granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med. 1983;98(1):76–85.
Fechner FP, Faquin WC, Pilch BZ. Wegener’s granulomatosis of the orbit: a clinicopathological study of 15 patients. Laryngoscope. 2002;112(11):1945–50.
Watkins AS, Kempen JH, Choi D, Liesegang TL, Pujari SS, Newcomb C, et al. Ocular disease in patients with ANCA-positive vasculitis. J Ocul Biol Dis Infor. 2009;3(1):12–9.
Levy-Clarke G, Ding X, Gangaputra S, Yeh S, Goodglick T, Byrnes G, et al. Recalcitrant granulomatous sclerouveitis in a patient with granulomatous ANCA-associated vasculitis. Ocul Immunol Inflamm. 2009;17(2):83–7.
Proia AD. Granulomatous choroiditis in Wegener granulomatosis. Arch Ophthalmol. 2011;129(4):520–1.
Iida T, Spaide RF, Kantor J. Retinal and choroidal arterial occlusion in Wegener’s granulomatosis. Am J Ophthalmol. 2002;133(1):151–2.
Levi M, Kodsi SR, Rubin SE, Lyons C, Golden R, Olitsky SE, et al. Ocular involvement as the initial manifestation of Wegener’s granulomatosis in children. J AAPOS. 2008;12(1):94–6.
Spalton DJ, Graham EM, Page NG, Sanders MD. Ocular changes in limited forms of Wegener’s granulomatosis. Br J Ophthalmol. 1981;65(8):553–63.
Parelhoff ES, Chavis RM, Friendly DS. Wegener’s granulomatosis presenting as orbital pseudotumor in children. J Pediatr Ophthalmol Strabismus. 1985;22(3):100–4.
Wardyn KA, Ycinska K, Matuszkiewicz-Rowinska J, Chipczynska M. Pseudotumour orbitae as the initial manifestation in Wegener’s granulomatosis in a 7-year-old girl. Clin Rheumatol. 2003;22(6):472–4.
Chipczynska B, Gralek M, Hautz W, Zegadlo-Mylik M, Kocyla-Karczmarewicz B, Kanigowska K, et al. Orbital tumor as an initial manifestation of Wegener’s granulomatosis in children: a series of four cases. Med Sci Monit. 2009;15(8):CS135–8.
Perry SR, Rootman J, White VA. The clinical and pathologic constellation of Wegener granulomatosis of the orbit. Ophthalmology. 1997;104(4):683–94.
Moorthy AV, Chesney RW, Segar WE, Groshong T. Wegener granulomatosis in childhood: prolonged survival following cytotoxic therapy. J Pediatr. 1977;91(4):616–8.
Sacks RD, Stock EL, Crawford SE, Greenwald MJ, O’Grady RB. Scleritis and Wegener’s granulomatosis in children. Am J Ophthalmol. 1991;111(4):430–3.
Muhle C, Reinhold-Keller E, Richter C, Duncker G, Beigel A, Brinkmann G, et al. MRI of the nasal cavity, the paranasal sinuses and orbits in Wegener’s granulomatosis. Eur Radiol. 1997;7(4):566–70.
Provenzale JM, Mukherji S, Allen NB, Castillo M, Weber AW. Orbital involvement by Wegener’s granulomatosis: imaging findings. AJR Am J Roentgenol. 1996;166(4):929–34.
Reuter M, Biederer J, Both M, Schnabel A, Reinhold-Keller E, Gross WL, et al. [Radiology of the primary systemic vasculitides]. RoFo. 2003;175(9):1184–92.
Courcoutsakis NA, Langford CA, Sneller MC, Cupps TR, Gorman K, Patronas NJ. Orbital involvement in Wegener granulomatosis: MR findings in 12 patients. J Comput Assist Tomogr. 1997;21(3):452–8.
Boulter EL, Eleftheriou D, Sebire NJ, Edelsten C, Brogan PA. Inflammatory lesions of the orbit: a single paediatric rheumatology centre experience. Rheumatology (Oxford). 2012;51(6):1070–5.
Kalina PH, Lie JT, Campbell RJ, Garrity JA. Diagnostic value and limitations of orbital biopsy in Wegener’s granulomatosis. Ophthalmology. 1992;99(1):120–4.
Gottlieb BS, Miller LC, Ilowite NT. Methotrexate treatment of Wegener granulomatosis in children. J Pediatr. 1996;129(4):604–7.
Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363(3):221–32.
Nowack R, Gobel U, Klooker P, Hergesell O, Andrassy K, van der Woude FJ. Mycophenolate mofetil for maintenance therapy of Wegener’s granulomatosis and microscopic polyangiitis: a pilot study in 11 patients with renal involvement. J Am Soc Nephrol. 1999;10(9):1965–71.
Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JW, Dadoniene J, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med. 2003;349(1):36–44.
Booth A, Harper L, Hammad T, Bacon P, Griffith M, Levy J, et al. Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol. 2004;15(3):717–21.
Seo P, Specks U, Keogh KA. Efficacy of rituximab in limited Wegener’s granulomatosis with refractory granulomatous manifestations. J Rheumatol. 2008;35(10):2017–23.
Martinez Del Pero M, Chaudhry A, Jones RB, Sivasothy P, Jani P, Jayne D. B-cell depletion with rituximab for refractory head and neck Wegener’s granulomatosis: a cohort study. Clin Otolaryngol. 2009;34(4):328–35.
Taylor SR, Salama AD, Joshi L, Pusey CD, Lightman SL. Rituximab is effective in the treatment of refractory ophthalmic Wegener’s granulomatosis. Arthritis Rheum. 2009;60(5):1540–7.
Kwan AS, Rose GE. Lacrimal drainage surgery in Wegener’s granulomatosis. Br J Ophthalmol. 2000;84(3):329–31.
Holds JB, Anderson RL, Wolin MJ. Dacryocystectomy for the treatment of dacryocystitis patients with Wegener’s granulomatosis. Ophthalmic Surg. 1989;20(6):443–4.
Cannady SB, Batra PS, Koening C, Lorenz RR, Citardi MJ, Langford C, et al. Sinonasal Wegener granulomatosis: a single-institution experience with 120 cases. Laryngoscope. 2009;119(4):757–61.
Levy-Clarke GA, Nussenblatt R. Retinal vasculitis. Int Ophthalmol Clin. 2005;45(2):99–113.
Scuccimarri R. Kawasaki disease. Pediatr Clin North Am. 2012;59(2):425–45.
Taubert KA, Rowley AH, Shulman ST. Nationwide survey of Kawasaki disease and acute rheumatic fever. J Pediatr. 1991;119(2):279–82.
Taubert K. Epidemiology of Kawasaki disease in the United States and worldwide. Prog Pediatr Cardiol. 1997;6(3):181–5.
Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation. 2004;110(17):2747–71.
Burns JC, Glode MP. Kawasaki syndrome. Lancet. 2004;364(9433):533–44.
Holman RC, Curns AT, Belay ED, Steiner CA, Effler PV, Yorita KL, et al. Kawasaki syndrome in Hawaii. Pediatr Infect Dis J. 2005;24(5):429–33.
Fujita Y, Nakamura Y, Sakata K, Hara N, Kobayashi M, Nagai M, et al. Kawasaki disease in families. Pediatrics. 1989;84(4):666–9.
Dergun M, Kao A, Hauger SB, Newburger JW, Burns JC. Familial occurrence of Kawasaki syndrome in North America. Arch Pediatr Adolesc Med. 2005;159(9):876–81.
Uehara R, Yashiro M, Nakamura Y, Yanagawa H. Kawasaki disease in parents and children. Acta Paediatr. 2003;92(6):694–7.
Burgner D, Davila S, Breunis WB, Ng SB, Li Y, Bonnard C, et al. A genome-wide association study identifies novel and functionally related susceptibility Loci for Kawasaki disease. PLoS Genet. 2009;5(1):e1000319.
Yeung R. The etiology of Kawasaki disease: a superantigen-mediated process. Prog Pediatr Cardiol. 2004;19(2):115–22.
Cimaz R, Sundel R. Atypical and incomplete Kawasaki disease. Best Pract Res Clin Rheumatol. 2009;23(5):689–97.
Kawasaki T. [Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children]. Arerugi. 1967;16(3):178–222.
Melish ME, Hicks RM, Larson EJ. Mucocutaneous lymph node syndrome in the United States. Am J Dis Child. 1976;130(6):599–607.
Kawasaki T, Kosaki F, Okawa S, Shigematsu I, Yanagawa H. A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan. Pediatrics. 1974;54(3):271–6.
Germain BF, Moroney JD, Guggino GS, Cimino L, Rodriguez C, Bocanegra TS. Anterior uveitis in Kawasaki disease. J Pediatr. 1980;97(5):780–1.
Yanagawa H, Nakamura Y, Yashiro M, Ojima T, Tanihara S, Oki I, et al. Results of the nationwide epidemiologic survey of Kawasaki disease in 1995 and 1996 in Japan. Pediatrics. 1998;102(6), E65.
Nakamura Y, Yashiro M, Uehara R, Sadakane A, Chihara I, Aoyama Y, et al. Epidemiologic features of Kawasaki disease in Japan: results of the 2007–2008 nationwide survey. J Epidemiol. 2010;20(4):302–7.
Holman RC, Belay ED, Christensen KY, Folkema AM, Steiner CA, Schonberger LB. Hospitalizations for Kawasaki syndrome among children in the United States, 1997–2007. Pediatr Infect Dis J. 2010;29(6):483–8.
Momenah T, Sanatani S, Potts J, Sandor GG, Human DG, Patterson MW. Kawasaki disease in the older child. Pediatrics. 1998;102(1), e7.
Stockheim JA, Innocentini N, Shulman ST. Kawasaki disease in older children and adolescents. J Pediatr. 2000;137(2):250–2.
Lin YT, Manlhiot C, Ching JC, Han RK, Nield LE, Dillenburg R, et al. Repeated systematic surveillance of Kawasaki disease in Ontario from 1995 to 2006. Pediatr Int. 2010;52(5):699–706.
Lang B. Recognizing Kawasaki disease. Paediatr Child Health. 2001;6(9):638–43.
Friter BS, Lucky AW. The perineal eruption of Kawasaki syndrome. Arch Dermatol. 1988;124(12):1805–10.
Yoskovitch A, Tewfik TL, Duffy CM, Moroz B. Head and neck manifestations of Kawasaki disease. Int J Pediatr Otorhinolaryngol. 2000;52(2):123–9.
Gong GW, McCrindle BW, Ching JC, Yeung RS. Arthritis presenting during the acute phase of Kawasaki disease. J Pediatr. 2006;148(6):800–5.
Baker AL, Lu M, Minich LL, Atz AM, Klein GL, Korsin R, et al. Associated symptoms in the ten days before diagnosis of Kawasaki disease. J Pediatr. 2009;154(4):592–5.e2.
Matsuura H, Ishikita T, Yamamoto S, Umezawa T, Ito R, Hashiguchi R, et al. Gallium-67 myocardial imaging for the detection of myocarditis in the acute phase of Kawasaki disease (mucocutaneous lymph node syndrome): the usefulness of single photon emission computed tomography. Br Heart J. 1987;58(4):385–92.
Kato H, Ichinose E, Kawasaki T. Myocardial infarction in Kawasaki disease: clinical analyses in 195 cases. J Pediatr. 1986;108(6):923–7.
Newburger JW, Takahashi M, Burns JC, Beiser AS, Chung KJ, Duffy CE, et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med. 1986;315(6):341–7.
Jacob JL, Polomeno RC, Chad Z, Lapointe N. Ocular manifestations of Kawasaki disease (mucocutaneous lymph node syndrome). Can J Ophthalmol. 1982;17(5):199–202.
Ohno S, Miyajima T, Higuchi M, Yoshida A, Matsuda H, Saheki Y, et al. Ocular manifestations of Kawasaki’s disease (mucocutaneous lymph node syndrome). Am J Ophthalmol. 1982;93(6):713–7.
Blatt AN, Vogler L, Tychsen L. Incomplete presentations in a series of 37 children with Kawasaki disease: the role of the pediatric ophthalmologist. J Pediatr Ophthalmol Strabismus. 1996;33(2):114–9.
Puglise JV, Rao NA, Weiss RA, Phillips TM, Marak Jr GE. Ocular features of Kawasaki’s disease. Arch Ophthalmol. 1982;100(7):1101–3.
Rennebohm RM, Burke MJ, Crowe W, Levinson JE. Anterior uveitis in Kawasaki’s disease. Am J Ophthalmol. 1981;91(4):535–7.
Ryan EH, Walton DS. Conjunctival scarring in Kawasaki disease: a new finding? J Pediatr Ophthalmol Strabismus. 1983;20(3):106–8.
Smith LB, Newburger JW, Burns JC. Kawasaki syndrome and the eye. Pediatr Infect Dis J. 1989;8(2):116–8.
Burke MJ, Rennebohm RM, Crowe W, Levinson JE. Follow-up ophthalmologic examinations in children with Kawasaki’s disease. Am J Ophthalmol. 1981;91(4):537–9.
Anand S, Yang YC. Optic disc changes in Kawasaki disease. J Pediatr Ophthalmol Strabismus. 2004;41(3):177–9.
Kadyan A, Choi J, Headon MP. Disciform keratitis and optic disc swelling in Kawasaki disease: an unusual presentation. Eye (Lond). 2006;20(8):976–7.
Felz MW, Patni A, Brooks SE, Tesser RA. Periorbital vasculitis complicating Kawasaki syndrome in an infant. Pediatrics. 1998;101(6), E9.
Font RL, Mehta RS, Streusand SB, O’Boyle TE, Kretzer FL. Bilateral retinal ischemia in Kawasaki disease. Postmortem findings and electron microscopic observations. Ophthalmology. 1983;90(5):569–77.
Burns JC, Best BM, Mejias A, Mahony L, Fixler DE, Jafri HS, et al. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. J Pediatr. 2008;153(6):833–8.
Son MB, Gauvreau K, Burns JC, Corinaldesi E, Tremoulet AH, Watson VE, et al. Infliximab for intravenous immunoglobulin resistance in Kawasaki disease: a retrospective study. J Pediatr. 2011;158(4):644–9.e1.
Mori M, Imagawa T, Hara R, Kikuchi M, Hara T, Nozawa T, et al. Efficacy and limitation of infliximab treatment for children with Kawasaki disease intractable to intravenous immunoglobulin therapy: report of an open-label case series. J Rheumatol. 2012;39(4):864–7.
Ozen S, Anton J, Arisoy N, Bakkaloglu A, Besbas N, Brogan P, et al. Juvenile polyarteritis: results of a multicenter survey of 110 children. J Pediatr. 2004;145(4):517–22.
Reimold EW, Weinberg AG, Fink CW, Battles ND. Polyarteritis in children. Am J Dis Child. 1976;130(5):534–41.
Dillon MJ, Ozen S. Polyarteritis nodosa and cutaneous polyarteritis nodosa. In: Cassidy JT, Petty RE, Laxer RM, Lindsley CB, editors. Textbook of pediatric rheumatology. 6th ed. Philadalphia: Saunders; 2011. p. 498–504.
Ozen S, Saatci U, Balkanci F, Besbas N, Bakkaloglu A, Tacal T. Familial Mediterranean fever and polyarteritis nodosa. Scand J Rheumatol. 1992;21(6):312–3.
Kocak H, Cakar N, Hekimoglu B, Atakan C, Akkok N, Unal S. The coexistence of familial Mediterranean fever and polyarteritis nodosa; report of a case. Pediatr Nephrol. 1996;10(5):631–3.
Bakkaloglu SA, Muzac S, Akpek S, Soylemezoglu O, Buyan N, Hasanoglu E. Polyarteritis nodosa in a case of familial Mediterranean fever. Pediatr Nephrol. 2004;19(5):536–8.
Brogan PA. What’s new in the aetiopathogenesis of vasculitis? Pediatr Nephrol. 2007;22(8):1083–94.
Kussmaul A, Maier R. Ueber eine bisher nicht beschriebene eigenthümliche Arterienerkrankung (Periarteritis nodosa), die mit Morbus Brightii und rapid fortschreitender allgemeiner Muskellähmung einhergeht. Dtsch Arch Klin Med. 1866;1:484–518.
Dillon MJ, Eleftheriou D, Brogan PA. Medium-size-vessel vasculitis. Pediatr Nephrol. 2010;25(9):1641–52.
Fink CW. Polyarteritis and other diseases with necrotizing vasculitis in childhood. Arthritis Rheum. 1977;20(2 Suppl):378–84.
Frohnert PP, Sheps SG. Long-term follow-up study of periarteritis nodosa. Am J Med. 1967;43(1):8–14.
Ozen S, Besbas N, Saatci U, Bakkaloglu A. Diagnostic criteria for polyarteritis nodosa in childhood. J Pediatr. 1992;120(2 Pt 1):206–9.
Maeda M, Kobayashi M, Okamoto S, Fuse T, Matsuyama T, Watanabe N, et al. Clinical observation of 14 cases of childhood polyarteritis nodosa in Japan. Acta Paediatr Jpn. 1997;39(2):277–9.
Fink CW. Vasculitis. Pediatr Clin North Am. 1986;33(5):1203–19.
Magilavy DB, Petty RE, Cassidy JT, Sullivan DB. A syndrome of childhood polyarteritis. J Pediatr. 1977;91(1):25–30.
Ettlinger RE, Nelson AM, Burke EC, Lie JT. Polyarteritis nodosa in childhood a clinical pathologic study. Arthritis Rheum. 1979;22(8):820–5.
Eleftheriou D, Dillon MJ, Brogan PA. Advances in childhood vasculitis. Curr Opin Rheumatol. 2009;21(4):411–8.
Topaloglu R, Besbas N, Saatci U, Bakkaloglu A, Oner A. Cranial nerve involvement in childhood polyarteritis nodosa. Clin Neurol Neurosurg. 1992;94(1):11–3.
Engel DG, Gospe Jr SM, Tracy KA, Ellis WG, Lie JT. Fatal infantile polyarteritis nodosa with predominant central nervous system involvement. Stroke. 1995;26(4):699–701.
Besbas N, Ozen S, Saatci U, Topaloglu R, Tinaztepe K, Bakkaloglu A. Renal involvement in polyarteritis nodosa: evaluation of 26 Turkish children. Pediatr Nephrol. 2000;14(4):325–7.
Cakar N, Ozcakar ZB, Soy D, Ucar Y, Fitoz S, Kara N, et al. Renal involvement in childhood vasculitis. Nephron Clin Pract. 2008;108(3):c202–6.
Tasdemir I, Turgan C, Emri S, Yasavul U, Caglar S, Bakkaloglu M, et al. Spontaneous perirenal haematoma secondary to polyarteritis nodosa. Br J Urol. 1988;62(3):219–22.
Roberts FB, Fetterman GH. Polyarteritis Nodosa in Infancy. J Pediatr. 1963;63:519–29.
McLain LG, Kelsch RC, Bookstein JJ. Polyarteritis nodosa diagnosed by renal arteriography. J Pediatr. 1972;80(6):1032–5.
Akova YA, Jabbur NS, Foster CS. Ocular presentation of polyarteritis nodosa. Clinical course and management with steroid and cytotoxic therapy. Ophthalmology. 1993;100(12):1775–81.
Hsu CT, Kerrison JB, Miller NR, Goldberg MF. Choroidal infarction, anterior ischemic optic neuropathy, and central retinal artery occlusion from polyarteritis nodosa. Retina. 2001;21(4):348–51.
Kimbrell Jr OC, Wheliss JA. Polyarteritis nodosa complicated by bilateral optic neuropathy. J Am Med Assoc. 1967;201(1):139–40.
Rosen ES. The retinopathy in polyarteritis nodosa. Br J Ophthalmol. 1968;52(12):903–6.
Ford RG, Siekert RG. Central Nervous System Manifestations of Periarteritis Nodosa. Neurology. 1965;15:114–22.
Leung AC, McLay A, Boulton-Jones JM. Polyarteritis presenting with thrombocytosis and central retinal vein thrombosis. Scott Med J. 1987;32(1):24–6.
Dillon MJ. Vasculitis treatment—new therapeutic approaches. Eur J Pediatr. 2006;165(6):351–7.
Wright E, Dillon MJ, Tullus K. Childhood vasculitis and plasma exchange. Eur J Pediatr. 2007;166(2):145–51.
Eleftheriou D, Melo M, Marks SD, Tullus K, Sills J, Cleary G, et al. Biologic therapy in primary systemic vasculitis of the young. Rheumatology (Oxford). 2009;48(8):978–86.
Cakar N, Yalcinkaya F, Duzova A, Caliskan S, Sirin A, Oner A, et al. Takayasu arteritis in children. J Rheumatol. 2008;35(5):913–9.
Johnston SL, Lock RJ, Gompels MM. Takayasu arteritis: a review. J Clin Pathol. 2002;55(7):481–6.
Hall S, Barr W, Lie JT, Stanson AW, Kazmier FJ, Hunder GG. Takayasu arteritis. A study of 32 North American patients. Medicine. 1985;64(2):89–99.
Nazareth R, Mason JC. Takayasu arteritis: severe consequences of delayed diagnosis. QJM. 2011;104(9):797–800.
Mason JC. Takayasu arteritis—advances in diagnosis and management. Nat Rev Rheumatol. 2010;6(7):406–15.
Kerr GS, Hallahan CW, Giordano J, Leavitt RY, Fauci AS, Rottem M, et al. Takayasu arteritis. Ann Intern Med. 1994;120(11):919–29.
Hotchi M. Pathological studies on Takayasu arteritis. Heart Vessels Suppl. 1992;7:11–7.
Weyand CM, Goronzy JJ. Medium- and large-vessel vasculitis. N Engl J Med. 2003;349(2):160–9.
Mwipatayi BP, Jeffery PC, Beningfield SJ, Matley PJ, Naidoo NG, Kalla AA, et al. Takayasu arteritis: clinical features and management: report of 272 cases. ANZ J Surg. 2005;75(3):110–7.
Subramanyan R, Joy J, Balakrishnan KG. Natural history of aortoarteritis (Takayasu’s disease). Circulation. 1989;80(3):429–37.
Ishikawa K, Maetani S. Long-term outcome for 120 Japanese patients with Takayasu’s disease. Clinical and statistical analyses of related prognostic factors. Circulation. 1994;90(4):1855–60.
Maksimowicz-McKinnon K, Clark TM, Hoffman GS. Limitations of therapy and a guarded prognosis in an American cohort of Takayasu arteritis patients. Arthritis Rheum. 2007;56(3):1000–9.
Park MC, Lee SW, Park YB, Chung NS, Lee SK. Clinical characteristics and outcomes of Takayasu’s arteritis: analysis of 108 patients using standardized criteria for diagnosis, activity assessment, and angiographic classification. Scand J Rheumatol. 2005;34(4):284–92.
Rose AG, Sinclair-Smith CC. Takayasu’s arteritis. A study of 16 autopsy cases. Arch Pathol Lab Med. 1980;104(5):231–7.
Pantell RH, Goodman Jr BW. Takayasu’s arteritis: the relationship with tuberculosis. Pediatrics. 1981;67(1):84–8.
Aggarwal A, Chag M, Sinha N, Naik S. Takayasu’s arteritis: role of Mycobacterium tuberculosis and its 65 kDa heat shock protein. Int J Cardiol. 1996;55(1):49–55.
Fraga A, Mintz G, Valle L, Flores-Izquierdo G. Takayasu’s arteritis: frequency of systemic manifestations (study of 22 patients) and favorable response to maintenance steroid therapy with adrenocorticosteroids (12 patients). Arthritis Rheum. 1972;15(6):617–24.
Lande A, Rossi P. The value of total aortography in the diagnosis of Takayasu’s arteritis. Radiology. 1975;114(2):287–97.
Shelhamer JH, Volkman DJ, Parrillo JE, Lawley TJ, Johnston MR, Fauci AS. Takayasu’s arteritis and its therapy. Ann Intern Med. 1985;103(1):121–6.
Jain S, Kumari S, Ganguly NK, Sharma BK. Current status of Takayasu arteritis in India. Int J Cardiol. 1996;54(Suppl):S111–6.
Hahn D, Thomson PD, Kala U, Beale PG, Levin SE. A review of Takayasu’s arteritis in children in Gauteng, South Africa. Pediatr Nephrol. 1998;12(8):668–75.
Lupi-Herrera E, Sanchez-Torres G, Marcushamer J, Mispireta J, Horwitz S, Vela JE. Takayasu’s arteritis. Clinical study of 107 cases. Am Heart J. 1977;93(1):94–103.
Dabague J, Reyes PA. Takayasu arteritis in Mexico: a 38-year clinical perspective through literature review. Int J Cardiol. 1996;54(Suppl):S103–9.
Muranjan MN, Bavdekar SB, More V, Deshmukh H, Tripathi M, Vaswani R. Study of Takayasu’s arteritis in children: clinical profile and management. J Postgrad Med. 2000;46(1):3–8.
Rosenthal T, Morag B, Itzchak Y. Takayasu arteritis in Israel. Heart Vessels Suppl. 1992;7:44–7.
Koide K. Takayasu arteritis in Japan. Heart Vessels Suppl. 1992;7:48–54.
Takayasu M. On the unusual transformation of symptoms of retinal vessels. Acta Soc Ophth Japan. 1908;12:554–5.
Numano F, Kakuta T. Takayasu arteritis—five doctors in the history of Takayasu arteritis. Int J Cardiol. 1996;54(Suppl):S1–10.
Ask-Upmark E. On the pulseless disease outside of Japan. Acta Med Scand. 1954;149(3):161–78.
Brunner J, Armstrong D, Feldman BM, Schneider R, Benseler S. Childhood stroke as the presentation of Takayasu’s arteritis: diagnostic delay can cause catastrophic complications. J Rheumatol. 2008;35(6):1228–30.
Rossor E. Takayasu’s arteritis as a differential diagnosis of systemic juvenile chronic arthritis. Arch Dis Child. 1979;54(10):798–800.
Adderson EE, Shultz PK, Bohnsack JF. Radiological case of the month. Takayasu arteritis. Arch Pediatr Adolesc Med. 1999;153(9):995–6.
Brunner J, Feldman BM, Tyrrell PN, Kuemmerle-Deschner JB, Zimmerhackl LB, Gassner I, et al. Takayasu arteritis in children and adolescents. Rheumatology (Oxford). 2010;49(10):1806–14.
Ostler HB. Pulseless disease (Takayasu’s disease). Am J Ophthalmol. 1957;43(4 Part 1):583–9.
Edwards KK, Lindsley HB, Lai CW, Van Veldhuizen PJ. Takayasu arteritis presenting as retinal and vertebrobasilar ischemia. J Rheumatol. 1989;16(7):1000–2.
Peter J, David S, Danda D, Peter JV, Horo S, Joseph G. Ocular manifestations of Takayasu arteritis: a cross-sectional study. Retina. 2011;31(6):1170–8.
Karam EZ, Muci-Mendoza R, Hedges 3rd TR. Retinal findings in Takayasu’s arteritis. Acta Ophthalmol Scand. 1999;77(2):209–13.
Chun YS, Park SJ, Park IK, Chung H, Lee J. The clinical and ocular manifestations of Takayasu arteritis. Retina. 2001;21(2):132–40.
Uyama M, Asayama K, editors. Retinal vascular changes in Takayasu’s disease (pulseless disease), occurrence and Evolution of the lesion. In: International Symposium on Fluorescein Angiography 1976; Ghent.
Becker RW, Sohn RL, Poulik JM, Berguer R. Takayasu’s arteritis presenting as uveitis in a 5-year-old girl. Ann Vasc Surg. 2005;19(2):258–62.
McDonald MA, Ojaimi E, Favilla I. Anterior uveitis in a child with Takayasu’s arteritis. Clin Experiment Ophthalmol. 2004;32(3):336–9.
Kausman JY, Walker A, Piper S. Acute panuveitis and Takayasu’s arteritis. Arch Dis Child. 2003;88(10):938–9.
Peter J, David S, Joseph G, Horo S, Danda D. Hypoperfusive and hypertensive ocular manifestations in Takayasu arteritis. Clin Ophthalmol. 2010;4:1173–6.
Demir MN, Hazirolan D, Altiparmak UE, Acar MA, Unlu N, Ornek F. Takayasu’s disease and secondary ocular ischemic syndrome. J Pediatr Ophthalmol Strabismus. 2010;47(1):54–7.
Aluquin VP, Albano SA, Chan F, Sandborg C, Pitlick PT. Magnetic resonance imaging in the diagnosis and follow up of Takayasu’s arteritis in children. Ann Rheum Dis. 2002;61(6):526–9.
Appenzeller S, Faria AV, Zanardi VA, Fernandes SR, Costallat LT, Cendes F. Vascular involvement of the central nervous system and systemic diseases: etiologies and MRI findings. Rheumatol Int. 2008;28(12):1229–37.
Zheng D, Fan D, Liu L. Takayasu arteritis in China: a report of 530 cases. Heart Vessels Suppl. 1992;7:32–6.
Piyachon C, Suwanwela N. Takayasu arteritis in Thailand. Heart Vessels Suppl. 1992;7:60–7.
Morales E, Pineda C, Martinez-Lavin M. Takayasu’s arteritis in children. J Rheumatol. 1991;18(7):1081–4.
Ozen S, Duzova A, Bakkaloglu A, Bilginer Y, Cil BE, Demircin M, et al. Takayasu arteritis in children: preliminary experience with cyclophosphamide induction and corticosteroids followed by methotrexate. J Pediatr. 2007;150(1):72–6.
Filocamo G, Buoncompagni A, Viola S, Loy A, Malattia C, Ravelli A, et al. Treatment of Takayasu’s arteritis with tumor necrosis factor antagonists. J Pediatr. 2008;153(3):432–4.
Hoffman GS. Takayasu arteritis: lessons from the American National Institutes of Health experience. Int J Cardiol. 1996;54(Suppl):S99–102.
Hoffman GS, Merkel PA, Brasington RD, Lenschow DJ, Liang P. Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. Arthritis Rheum. 2004;50(7):2296–304.
Salvarani C, Magnani L, Catanoso MG, Pipitone N, Versari A, Dardani L, et al. Rescue treatment with tocilizumab for Takayasu arteritis resistant to TNF-alpha blockers. Clin Exp Rheumatol. 2012;30(1 Suppl 70):S90–3.
Unizony S, Arias-Urdaneta L, Miloslavsky E, Arvikar S, Khosroshahi A, Keroack B, et al. Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica. Arthritis Care Res. 2012;64(11):1720–9.
Bravo Mancheno B, Perin F, Guez Vazquez Del Rey Mdel M, Garcia Sanchez A, Alcazar Romero PP. Successful tocilizumab treatment in a child with refractory Takayasu arteritis. Pediatrics. 2012;130(6):e1720–4.
Giordano JM. Surgical treatment of Takayasu’s arteritis. Int J Cardiol. 2000;75 Suppl 1:S123–8.
Liang P, Tan-Ong M, Hoffman GS. Takayasu’s arteritis: vascular interventions and outcomes. J Rheumatol. 2004;31(1):102–6.
Liang P, Hoffman GS. Advances in the medical and surgical treatment of Takayasu arteritis. Curr Opin Rheumatol. 2005;17(1):16–24.
Mahdy RA, Nada WM, Fawzy KM, Alnashar HY, Almosalamy SM. Efficacy of intravitreal bevacizumab with panretinal photocoagulation followed by Ahmed valve implantation in neovascular glaucoma. J Glaucoma. 2013;22(9):768–72.
Wakabayashi T, Oshima Y, Sakaguchi H, Ikuno Y, Miki A, Gomi F, et al. Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases. Ophthalmology. 2008;115(9):1571–80, 80.e1–3.
Yazdani S, Hendi K, Pakravan M, Mahdavi M, Yaseri M. Intravitreal bevacizumab for neovascular glaucoma: a randomized controlled trial. J Glaucoma. 2009;18(8):632–7.
Sakane T, Takeno M, Suzuki N, Inaba G. Behcet’s disease. N Engl J Med. 1999;341(17):1284–91.
Yazici H, Fresko I, Yurdakul S. Behcet’s syndrome: disease manifestations, management, and advances in treatment. Nat Clin Pract Rheumatol. 2007;3(3):148–55.
Kaklamani VG, Vaiopoulos G, Kaklamanis PG. Behcet’s disease. Semin Arthritis Rheum. 1998;27(4):197–217.
Direskeneli H, Saruhan-Direskeneli G. The role of heat shock proteins in Behcet’s disease. Clin Exp Rheumatol. 2003;21(4 Suppl 30):S44–8.
Mendoza-Pinto C, Garcia-Carrasco M, Jimenez-Hernandez M, Jimenez Hernandez C, Riebeling-Navarro C, Nava Zavala A, et al. Etiopathogenesis of Behcet’s disease. Autoimmun Rev. 2010;9(4):241–5.
Tursen U. Pathophysiology of the Behcet’s disease. Pathol Res Int. 2012;2012:493015.
Salvarani C, Boiardi L, Mantovani V, Olivieri I, Ciancio G, Cantini F, et al. Association of MICA alleles and HLA-B51 in Italian patients with Behcet’s disease. J Rheumatol. 2001;28(8):1867–70.
Evaluation of diagnostic (‘classification’) criteria in Behcet’s disease—towards internationally agreed criteria. The International Study Group for Behcet’s disease. Br J Rheum. 1992;31(5):299–308.
Criteria for diagnosis of Behcet’s disease. International Study Group for Behcet’s disease. Lancet. 1990;335(8697):1078–80.
Feigenbaum A. Description of Behcet’s syndrome in the Hippocratic third book of endemic diseases. Br J Ophthalmol. 1956;40(6):355–7.
Adamantiades B, editor. A case of relapsing iritis with hypopyon (in Greek). In: Proceedings of the Medical Society of Athens; 1930.
Adamantiades B. Sur un cas d’iritis à hypopion récidivant. Ann Ocul (Paris). 1931;168:271–8.
Behcet H. Uber rezidivierende aphthose, durch ein Virus verusachte geschwure am Mund am Auge, und an den Genitalien. Dermatol Worcheschr. 1937;105:1152–7.
Jensen T. Ulcerous haemorrhagic colitis associated with Behçet’s syndrome. Ugeskr Laeger. 1941;106:176–80.
Zouboulis CC, Keitel W. A historical review of early descriptions of Adamantiades-Behcet’s disease. J Invest Dermatol. 2002;119(1):201–5.
Kone-Paut I, Geisler I, Wechsler B, Ozen S, Ozdogan H, Rozenbaum M, et al. Familial aggregation in Behcet’s disease: high frequency in siblings and parents of pediatric probands. J Pediatr. 1999;135(1):89–93.
Kim DK, Chang SN, Bang D, Lee ES, Lee S. Clinical analysis of 40 cases of childhood-onset Behcet’s disease. Pediatr Dermatol. 1994;11(2):95–101.
Sarica R, Azizlerli G, Kose A, Disci R, Ovul C, Kural Z. Juvenile Behcet’s disease among 1784 Turkish Behcet’s patients. Int J Dermatol. 1996;35(2):109–11.
Benamour S, Zeroual B, Alaoui FZ. Joint manifestations in Behcet’s disease. A review of 340 cases. Rev Rhum. 1998;65(5):299–307.
Kone-Paut I, Gorchakoff-Molinas A, Weschler B, Touitou I. Paediatric Behcet’s disease in France. Ann Rheum Dis. 2002;61(7):655–6.
Kari JA, Shah V, Dillon MJ. Behcet’s disease in UK children: clinical features and treatment including thalidomide. Rheumatology (Oxford). 2001;40(8):933–8.
Kone-Paut I, Yurdakul S, Bahabri SA, Shafae N, Ozen S, Ozdogan H, et al. Clinical features of Behcet’s disease in children: an international collaborative study of 86 cases. J Pediatr. 1998;132(4):721–5.
Krause I, Uziel Y, Guedj D, Mukamel M, Harel L, Molad Y, et al. Childhood Behcet’s disease: clinical features and comparison with adult-onset disease. Rheumatology (Oxford). 1999;38(5):457–62.
Karincaoglu Y, Borlu M, Toker SC, Akman A, Onder M, Gunasti S, et al. Demographic and clinical properties of juvenile-onset Behcet’s disease: a controlled multicenter study. J Am Acad Dermatol. 2008;58(4):579–84.
Gul A, Inanc M, Ocal L, Aral O, Konice M. Familial aggregation of Behcet’s disease in Turkey. Ann Rheum Dis. 2000;59(8):622–5.
Fresko I, Soy M, Hamuryudan V, Yurdakul S, Yavuz S, Tumer Z, et al. Genetic anticipation in Behcet’s syndrome. Ann Rheum Dis. 1998;57(1):45–8.
Sakane T, Suzuki N, Nagafuchi H. Etiopathology of Behcet’s disease: immunological aspects. Yonsei Med J. 1997;38(6):350–8.
Jorizzo JL. Behcet’s disease. Neurol Clin. 1987;5(3):427–40.
Shimizu T, Ehrlich GE, Inaba G, Hayashi K. Behcet disease (Behcet syndrome). Semin Arthritis Rheum. 1979;8(4):223–60.
Ozen S, Petty RE. Behçet disease. In: Cassidy JT, Petty RE, Laxer RM, Lindsley CB, editors. Textbook of pediatric rheumatology. 6th ed. Philadelphia: Saunders; 2011. p. 552–8.
Uziel Y, Brik R, Padeh S, Barash J, Mukamel M, Harel L, et al. Juvenile Behcet’s disease in Israel. The Pediatric Rheumatology Study Group of Israel. Clin Exp Rheumatol. 1998;16(4):502–5.
Bahabri SA. al-Mazyed A, al-Balaa S, el-Ramahi L, al-Dalaan A. Juvenile Behcet’s disease in Arab children. Clin Exp Rheumatol. 1996;14(3):331–5.
Lang BA, Laxer RM, Thorner P, Greenberg M, Silverman ED. Pediatric onset of Behcet’s syndrome with myositis: case report and literature review illustrating unusual features. Arthritis Rheum. 1990;33(3):418–25.
Stringer DA, Cleghorn GJ, Durie PR, Daneman A, Hamilton JR. Behcet’s syndrome involving the gastrointestinal tract—a diagnostic dilemma in childhood. Pediatr Radiol. 1986;16(2):131–4.
Ammann AJ, Johnson A, Fyfe GA, Leonards R, Wara DW, Cowan MJ. Behcet syndrome. J Pediatr. 1985;107(1):41–3.
Al-Araji A, Kidd DP. Neuro-Behcet’s disease: epidemiology, clinical characteristics, and management. Lancet Neurol. 2009;8(2):192–204.
Yazici H, Yurdakul S, Hamuryudan V. Behcet’s syndrome. Curr Opin Rheumatol. 1999;11(1):53–7.
Tugal-Tutkun I, Urgancioglu M. Childhood-onset uveitis in Behcet disease:a descriptive study of 36 cases. Am J Ophthalmol. 2003;136(6):1114–9.
Kramer M, Amer R, Mukamel M, Snir M, Jaouni T, Friling R. Uveitis in juvenile Behcet’s disease: clinical course and visual outcome compared with adult patients. Eye (Lond). 2009;23(11):2034–41.
Evereklioglu C. Current concepts in the etiology and treatment of Behcet disease. Surv Ophthalmol. 2005;50(4):297–350.
Kitaichi N, Ohno S. Behcet disease in children. Int Ophthalmol Clin. 2008;48(3):87–91.
Citirik M, Berker N, Songur MS, Soykan E, Zilelioglu O. Ocular findings in childhood-onset Behcet disease. J AAPOS. 2009;13(4):391–5.
Eldem B, Onur C, Ozen S. Clinical features of pediatric Behcet’s disease. J Pediatr Ophthalmol Strabismus. 1998;35(3):159–61.
Kesen MR, Goldstein DA, Tessler HH. Uveitis associated with pediatric behcet disease in the american midwest. Am J Ophthalmol. 2008;146(6):819–27.e2.
James DG, Spiteri MA. Behcet’s disease. Ophthalmology. 1982;89(11):1279–84.
Evereklioglu C. Ocular Behcet disease: current therapeutic approaches. Curr Opin Ophthalmol. 2011;22(6):508–16.
Sungur GK, Hazirolan D, Yalvac I, Ozer PA, Yuksel D, Vural ET, et al. Clinical and demographic evaluation of Behcet disease among different paediatric age groups. Br J Ophthalmol. 2009;93(1):83–7.
Nussenblatt RB, Palestine AG, Chan CC, Mochizuki M, Yancey K. Effectiveness of cyclosporin therapy for Behcet’s disease. Arthritis Rheum. 1985;28(6):671–9.
Hatemi G, Silman A, Bang D, Bodaghi B, Chamberlain AM, Gul A, et al. EULAR recommendations for the management of Behcet disease. Ann Rheum Dis. 2008;67(12):1656–62.
Arida A, Fragiadaki K, Giavri E, Sfikakis PP. Anti-TNF agents for Behcet’s disease: analysis of published data on 369 patients. Semin Arthritis Rheum. 2011;41(1):61–70.
Deuter CM, Kotter I, Wallace GR, Murray PI, Stubiger N, Zierhut M. Behcet’s disease: ocular effects and treatment. Prog Retin Eye Res. 2008;27(1):111–36.
Wechsler B, Bodaghi B, Huong DL, Fardeau C, Amoura Z, Cassoux N, et al. Efficacy of interferon alfa-2a in severe and refractory uveitis associated with Behcet’s disease. Ocul Immunol Inflamm. 2000;8(4):293–301.
Tugal-Tutkun I, Guney-Tefekli E, Urgancioglu M. Results of interferon-alfa therapy in patients with Behcet uveitis. Graefes Arch Clin Exp Ophthalmol. 2006;244(12):1692–5.
Gueudry J, Wechsler B, Terrada C, Gendron G, Cassoux N, Fardeau C, et al. Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Behcet disease. Am J Ophthalmol. 2008;146(6):837–44.e1.
Onal S, Kazokoglu H, Koc A, Akman M, Bavbek T, Direskeneli H, et al. Long-term efficacy and safety of low-dose and dose-escalating interferon alfa-2a therapy in refractory Behcet uveitis. Arch Ophthalmol. 2011;129(3):288–94.
Ohno S, Nakamura S, Hori S, Shimakawa M, Kawashima H, Mochizuki M, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behcet’s disease with refractory uveoretinitis. J Rheumatol. 2004;31(7):1362–8.
Yamada Y, Sugita S, Tanaka H, Kamoi K, Kawaguchi T, Mochizuki M. Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behcet disease. Br J Ophthalmol. 2010;94(3):284–8.
Yamada Y, Sugita S, Tanaka H, Kamoi K, Takase H, Mochizuki M. Timing of recurrent uveitis in patients with Behcet’s disease receiving infliximab treatment. Br J Ophthalmol. 2011;95(2):205–8.
Keino H, Okada AA, Watanabe T, Taki W. Decreased ocular inflammatory attacks and background retinal and disc vascular leakage in patients with Behcet’s disease on infliximab therapy. Br J Ophthalmol. 2011;95(9):1245–50.
Wechsler B, Sable-Fourtassou R, Bodaghi B, Huong DL, Cassoux N, Badelon I, et al. Infliximab in refractory uveitis due to Behcet’s disease. Clin Exp Rheumatol. 2004;22(4 Suppl 34):S14–6.
Tugal-Tutkun I, Mudun A, Urgancioglu M, Kamali S, Kasapoglu E, Inanc M, et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behcet’s disease: an open-label trial. Arthritis Rheum. 2005;52(8):2478–84.
Tabbara KF, Al-Hemidan AI. Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Behcet disease. Am J Ophthalmol. 2008;146(6):845–50.e1.
Letko E, Zafirakis P, Baltatzis S, Voudouri A, Livir-Rallatos C, Foster CS. Relapsing polychondritis: a clinical review. Semin Arthritis Rheum. 2002;31(6):384–95.
Gergely Jr P, Poor G. Relapsing polychondritis. Best Pract Res Clin Rheumatol. 2004;18(5):723–38.
Kent PD, Michet Jr CJ, Luthra HS. Relapsing polychondritis. Curr Opin Rheumatol. 2004;16(1):56–61.
Belot A, Duquesne A, Job-Deslandre C, Costedoat-Chalumeau N, Boudjemaa S, Wechsler B, et al. Pediatric-onset relapsing polychondritis: case series and systematic review. J Pediatr. 2010;156(3):484–9.
Hewagama A, Richardson B. The genetics and epigenetics of autoimmune diseases. J Autoimmun. 2009;33(1):3–11.
Zeuner M, Straub RH, Rauh G, Albert ED, Scholmerich J, Lang B. Relapsing polychondritis: clinical and immunogenetic analysis of 62 patients. J Rheumatol. 1997;24(1):96–101.
Lahmer T, Treiber M, von Werder A, Foerger F, Knopf A, Heemann U, et al. Relapsing polychondritis: an autoimmune disease with many faces. Autoimmun Rev. 2010;9(8):540–6.
Damiani JM, Levine HL. Relapsing polychondritis—report of ten cases. Laryngoscope. 1979;89(6 Pt 1):929–46.
Michet Jr CJ, McKenna CH, Luthra HS, O’Fallon WM. Relapsing polychondritis. Survival and predictive role of early disease manifestations. Ann Intern Med. 1986;104(1):74–8.
Jaksch-Watenhorst R. Polychondropathia. Wien Arch Inn Med. 1923;6:93–100.
Pearson CM, Kline HM, Newcomer VD. Relapsing polychondritis. N Engl J Med. 1960;263:51–8.
Rucker CW, Ferguson RH. Ocular Manifesations of Relapsing Polychondritis. Arch Ophthalmol. 1965;73:46–8.
Cohen PR, Rapini RP. Relapsing polychondritis. Int J Dermatol. 1986;25(5):280–5.
Trentham DE, Le CH. Relapsing polychondritis. Ann Intern Med. 1998;129(2):114–22.
McAdam LP, O’Hanlan MA, Bluestone R, Pearson CM. Relapsing polychondritis: prospective study of 23 patients and a review of the literature. Medicine. 1976;55(3):193–215.
Balsa A, Expinosa A, Cuesta M, MacLeod TI, Gijon-Banos J, Maddison PJ. Joint symptoms in relapsing polychondritis. Clin Exp Rheumatol. 1995;13(4):425–30.
Chang-Miller A, Okamura M, Torres VE, Michet CJ, Wagoner RD, Donadio Jr JV, et al. Renal involvement in relapsing polychondritis. Medicine. 1987;66(3):202–17.
Sundaram MB, Rajput AH. Nervous system complications of relapsing polychondritis. Neurology. 1983;33(4):513–5.
Del Rosso A, Petix NR, Pratesi M, Bini A. Cardiovascular involvement in relapsing polychondritis. Semin Arthritis Rheum. 1997;26(6):840–4.
Magargal LE, Donoso LA, Goldberg RE, Gonder J, Brodsky I. Ocular manifestations of relapsing polychondritis. Retina. 1981;1(2):96–9.
Isaak BL, Liesegang TJ, Michet Jr CJ. Ocular and systemic findings in relapsing polychondritis. Ophthalmology. 1986;93(5):681–9.
Knipp S, Bier H, Horneff G, Specker C, Schuster A, Schroten H, et al. Relapsing polychondritis in childhood—case report and short review. Rheumatol Int. 2000;19(6):231–4.
Matas BR. Iridocyclitis associated with relapsing polychondritis. Arch Ophthalmol. 1970;84(4):474–6.
Killian PJ, Susac J, Lawless OJ. Optic neuropathy in relapsing polychondritis. J Am Med Assoc. 1978;239(1):49–50.
Anderson Sr B. Ocular lesions in relapsing polychondritis and other rheumatoid syndromes. The Edward Jackson memorial lecture. Am J Ophthalmol. 1967;64(1):35–50.
Matoba A, Plager S, Barber J, McCulley JP. Keratitis in relapsing polychondritis. Ann Ophthalmol. 1984;16(4):367–70.
Stiles MC, Khan JA. Relapsing polychondritis. Arch Ophthalmol. 1989;107(2):277.
McKay DA, Watson PG, Lyne AJ. Relapsing polychondritis and eye disease. Br J Ophthalmol. 1974;58(6):600–5.
Peebo BB, Peebo M, Frennesson C. Relapsing polychondritis: a rare disease with varying symptoms. Acta Ophthalmol Scand. 2004;82(4):472–5.
Ridgway HB, Hansotia PL, Schorr WF. Relapsing polychondritis: unusual neurological findings and therapeutic efficacy of dapsone. Arch Dermatol. 1979;115(1):43–5.
Dolan DL, Lemmon Jr GB, Teitelbaum SL. Relapsing polychondritis. Analytical literature review and studies on pathogenesis. Am J Med. 1966;41(2):285–99.
Cutolo M, Seriolo B, Pizzorni C, Secchi ME, Soldano S, Paolino S, et al. Use of glucocorticoids and risk of infections. Autoimmun Rev. 2008;8(2):153–5.
Kemta Lekpa F, Kraus VB, Chevalier X. Biologics in relapsing polychondritis: a literature review. Semin Arthritis Rheum. 2012;41(5):712–9.
Preston SJ, Arnold MH, Buchanan WW. Sjogren’s syndrome beyond the eye. Aust N Z J Ophthalmol. 1989;17(2):111–20.
Cimaz R, Casadei A, Rose C, Bartunkova J, Sediva A, Falcini F, et al. Primary Sjogren syndrome in the paediatric age: a multicentre survey. Eur J Pediatr. 2003;162(10):661–5.
Bartunkova J, Sediva A, Vencovsky J, Tesar V. Primary Sjogren’s syndrome in children and adolescents: proposal for diagnostic criteria. Clin Exp Rheumatol. 1999;17(3):381–6.
Drosos AA, Tsiakou EK, Tsifetaki N, Politi EN, Siamopoulou-Mavridou A. Subgroups of primary Sjogren’s syndrome. Sjogren’s syndrome in male and paediatric Greek patients. Ann Rheum Dis. 1997;56(5):333–5.
Voulgarelis M, Skopouli FN. Clinical, immunologic, and molecular factors predicting lymphoma development in Sjogren’s syndrome patients. Clin Rev Allergy Immunol. 2007;32(3):265–74.
Nikolov NP, Illei GG. Pathogenesis of Sjogren's syndrome. Curr Opin Rheumatol. 2009;21(5):465–70.
Delaleu N, Jonsson MV, Appel S, Jonsson R. New concepts in the pathogenesis of Sjogren’s syndrome. Rheum Dis Clin North Am. 2008;34(4):833–45, vii.
Novljan MP, Rozman B, Jerse M, Rotar Z, Vidmar G, Kveder T, et al. Comparison of the different classification criteria sets for primary Sjogren's syndrome. Scand J Rheumatol. 2006;35(6):463–7.
Houghton K, Malleson P, Cabral D, Petty R, Tucker L. Primary Sjogren's syndrome in children and adolescents: are proposed diagnostic criteria applicable? J Rheumatol. 2005;32(11):2225–32.
Leber. Ueber die Entstehung der Netzhautablosung. Ber Versamml Ophthal Ges Stuttg. 1882;(14):165.
Sjogren H. Zur Kenntnis der Keratoconjunctivitis sicca (Keratitis filiformis bei Hypunfunktion der Tranendrusen). Acta Ophthalmol. 1933;11:1.
Manthorpe R. The man behind the syndrome: Henrik Sjogren. He elucidated the importance of tear production for the eye. Lakartidningen. 1987;84(47):3937–8.
Alamanos Y, Tsifetaki N, Voulgari PV, Venetsanopoulou AI, Siozos C, Drosos AA. Epidemiology of primary Sjogren's syndrome in north-west Greece, 1982–2003. Rheumatology (Oxford). 2006;45(2):187–91.
Pillemer SR, Matteson EL, Jacobsson LT, Martens PB, Melton 3rd LJ, O'Fallon WM, et al. Incidence of physician-diagnosed primary Sjogren syndrome in residents of Olmsted County, Minnesota. Mayo Clin Proc. 2001;76(6):593–9.
Anaya JM, Ogawa N, Talal N. Sjogren's syndrome in childhood. J Rheumatol. 1995;22(6):1152–8.
Singer NG, Tomanova-Soltys I, Lowe R. Sjogren's syndrome in childhood. Curr Rheumatol Rep. 2008;10(2):147–55.
Saad Magalhaes C, de Souza Medeiros PB, Oliveira-Sato J, Custodio-Domingues MA. Clinical presentation and salivary gland histopathology of paediatric primary Sjogren's syndrome. Clin Exp Rheumatol. 2011;29(3):589–93.
Tucker LB. Sjogren syndrome. In: Cassidy JT, Petty RE, Laxer RM, Lindsley CB, editors. Textbook of pediatric rheumatology. 6th ed. Philadelphia: Saunders; 2011. p. 458–65.
Pessler F, Emery H, Dai L, Wu YM, Monash B, Cron RQ, et al. The spectrum of renal tubular acidosis in paediatric Sjogren syndrome. Rheumatology (Oxford). 2006;45(1):85–91.
Bloch KJ, Buchanan WW, Wohl MJ, Bunim JJ. Sjoegren's Syndrome. A Clinical, Pathological, and Serological Study of Sixty-Two Cases. Medicine. 1965;44:187–231.
Tabbara KF, Vera-Cristo CL. Sjogren syndrome. Curr Opin Ophthalmol. 2000;11(6):449–54.
Ormerod LD, Fong LP, Foster CS. Corneal infection in mucosal scarring disorders and Sjogren's syndrome. Am J Ophthalmol. 1988;105(5):512–8.
Maeno N, Takei S, Imanaka H, Oda H, Yanagi K, Hayashi Y, et al. Anti-alpha-fodrin antibodies in Sjogren's syndrome in children. J Rheumatol. 2001;28(4):860–4.
Salaffi F, Argalia G, Carotti M, Giannini FB, Palombi C. Salivary gland ultrasonography in the evaluation of primary Sjogren's syndrome. Comparison with minor salivary gland biopsy. J Rheumatol. 2000;27(5):1229–36.
Ramos-Casals M, Solans R, Rosas J, Camps MT, Gil A, Del Pino-Montes J, et al. Primary Sjogren syndrome in Spain: clinical and immunologic expression in 1010 patients. Medicine. 2008;87(4):210–9.
McGuirt Jr WF, Whang C, Moreland W. The role of parotid biopsy in the diagnosis of pediatric Sjogren syndrome. Arch Otolaryngol Head Neck Surg. 2002;128(11):1279–81.
Mavragani CP, Moutsopoulos NM, Moutsopoulos HM. The management of Sjogren's syndrome. Nat Clin Pract Rheumatol. 2006;2(5):252–61.
Venables PJ. Management of patients presenting with Sjogren's syndrome. Best Pract Res Clin Rheumatol. 2006;20(4):791–807.
Ramos-Casals M, Tzioufas AG, Stone JH, Siso A, Bosch X. Treatment of primary Sjogren syndrome: a systematic review. J Am Med Assoc. 2010;304(4):452–60.
Williamson J, Doig WM, Forrester JV, Tham MH, Wilson T, Whaley K, et al. Management of the dry eye in Sjogren's syndrome. Br J Ophthalmol. 1974;58(9):798–805.
Hong S, Kim T, Chung SH, Kim EK, Seo KY. Recurrence after topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjogren's syndrome. J Ocul Pharmacol Ther. 2007;23(1):78–82.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Walton, R.C., Lin, C., Enzenauer, R.W. (2017). Ocular Manifestations of Pediatric Rheumatic Diseases. In: Levin, A., Enzenauer, R. (eds) The Eye in Pediatric Systemic Disease. Springer, Cham. https://doi.org/10.1007/978-3-319-18389-3_20
Download citation
DOI: https://doi.org/10.1007/978-3-319-18389-3_20
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-18388-6
Online ISBN: 978-3-319-18389-3
eBook Packages: MedicineMedicine (R0)